A Double-Blind, Randomized, Parallel-Group Study to Evaluate Long-Term Safety, Tolerability, and Efficacy of a Fixed Dose Combination GSP 301 Nasal Spray Compared With Two Placebo Nasal Spray Formulations in Subjects (Aged 12 Years and Older) With Perennial Allergic Rhinitis (PAR)
Phase: PHASE3
Conditions: Perennial Allergic Rhinitis
Sponsor: Glenmark Specialty S.A.

GSP 301-303 
GPL/CT/2014/018/III  
Version 2.0 
 
Date 31-Aug-2016 
 
CLINICAL STUDY PROTOCOL 
 
 
Protocol Title 
A Double-Blind, Randomized, Parallel-Group Study to Evaluate Long-
Term Safety, Tolerability, and Efficacy of a Fixed Dose Combination 
GSP 301 Nasal Spray Compared with Two Placebo Nasal Spray 
Formulations in Subjects (Aged 12 Years and Older) with Perennial 
Allergic Rhinitis (PAR) 
Protocol Number 
Study Number 
GPL/CT/2014/018/III 
GSP 301-303 
Name of Investigational 
Product/Code  
Fixed Dose Combination of Olopatadine Hydrochloride and Mometasone 
Furoate (GSP 301) 
Phase of Development 
Phase 3 
Sponsor 
Glenmark Specialty S.A. 
Avenue Léopold-Robert 37  
2300 La Chaux-de-Fonds 
Switzerland 
Protocol Version 
Version 2.0 
Amendment 1.0 
Date 
31-Aug-2016 
Supersedes 
Protocol 1.0 
25 Jan 2015 v1.0 
 
 
PROTOCOL HISTORY 
Original protocol 
Version 1.0 25 Jan 2016 
 
 
Statement of Confidentiality 
 
This protocol is a confidential document owned by Glenmark (Sponsor). Any unpublished information 
contained in it may not be disclosed to a third party without prior written approval of the Sponsor. 
However, the document may be disclosed to an Institutional Review Board/Independent Ethics 
Committee or a statutory regulatory authority under a similar condition of confidentiality. 
 
 
Glenmark  
CONFIDENTIAL 
Page 1 of 91 

GSP 301-303 
GPL/CT/2014/018/III  
Version 2.0 
 
Date 31-Aug-2016 
TABLE OF CONTENTS 
CLINICAL STUDY PROTOCOL ...............................................................................................1 
Table of Contents ...........................................................................................................................2 
List of Figures .................................................................................................................................5 
List of Appendices ..........................................................................................................................5 
1 
Abbreviations and Specialist Terms .....................................................................................6 
2 
Protocol Synopsis ....................................................................................................................8 
3 
Investigator’s Signature .......................................................................................................17 
4 
Sponsor’s Signature ..............................................................................................................18 
5 
Background Information .....................................................................................................19 
5.1 
Introduction ......................................................................................................................19 
5.2 
Investigational Product: Mechanism of Action .............................................................19 
5.3 
Preclinical Experience .....................................................................................................20 
5.4 
Clinical Experience ..........................................................................................................21 
5.5 
Study Rationale ................................................................................................................22 
5.6 
Benefit-Risk Assessment ..................................................................................................23 
6 
Study Objectives ...................................................................................................................24 
6.1 
Primary Objective ............................................................................................................24 
6.2 
Secondary Objective ........................................................................................................24 
6.3 
Exploratory Objective .....................................................................................................24 
7 
Study Design ..........................................................................................................................24 
7.1 
Study Type/Design ...........................................................................................................24 
7.2 
Discussion of Study Design, Including Choice of Control Groups ..............................26 
8 
Study Endpoints ....................................................................................................................26 
8.1 
Primary Endpoints...........................................................................................................26 
8.2 
Secondary Endpoints .......................................................................................................27 
8.2.1 
Efficacy Endpoints .....................................................................................................27 
8.2.2 
Other Efficacy Endpoints ..........................................................................................27 
8.3 
Exploratory Endpoint ......................................................................................................27 
8.4 
Appropriateness of Measurements .................................................................................28 
9 
Subject Selection and Withdrawal Criteria .......................................................................28 
9.1 
Inclusion Criteria .............................................................................................................28 
9.2 
Exclusion Criteria ............................................................................................................28 
9.3 
Randomization Criteria...................................................................................................31 
9.4 
Subject Discontinuation/Withdrawal Criteria ..............................................................31 
9.5 
Sponsor Discontinuation Criteria ...................................................................................32 
9.6 
Prior and Concomitant Medications ..............................................................................33 
9.7 
Lifestyle and/or Dietary Restrictions .............................................................................35 
10 Treatment of Subjects ..........................................................................................................35 
10.1 
Treatments Administered ...............................................................................................35 
10.1.1 
Administration ...........................................................................................................36 
10.1.2 
Treatment Adherence/Compliance ..........................................................................36 
10.1.3 
Treatment of Investigational Product Overdose .....................................................37 
10.2 
Identity of Investigational Products ...............................................................................37 
10.2.1 
Chemical Name and Structural Formulas ...............................................................37 
10.2.2 
Placebo ........................................................................................................................38 
Glenmark  
CONFIDENTIAL 
Page 2 of 91 

GSP 301-303 
GPL/CT/2014/018/III  
Version 2.0 
 
Date 31-Aug-2016 
10.2.3 
Packaging and Labeling of Investigational Products .............................................38 
10.3 
Allocation to Treatment Groups.....................................................................................38 
10.4 
Blinding and Unblinding Procedures .............................................................................39 
10.5 
Preparation, Receipt, Storage, Dispensing and Accountability ...................................39 
11 Timing of study procedures and assessments ....................................................................39 
11.1 
Screening Visit: Visit 1 (Day -7 to -10) ...........................................................................40 
11.2 
Randomization Visit: Visit 2 (Day 1) .............................................................................41 
11.3 
Treatment Visit: Visit 3 (Week 3 ±3 Days) ....................................................................42 
11.4 
Treatment Visit: Visit 4 (Week 6 ±3 Days) ....................................................................42 
11.5 
Treatment Visit: Visit 5 (Week 12 ±5 Days) ..................................................................43 
11.6 
Treatment Visit: Visit 6 (Week 18 ±7 Days) ..................................................................43 
11.7 
Treatment Visit: Visit 7 (Week 24 ±7 Days) ..................................................................43 
11.8 
Treatment Visit: Visit 8 (Week 30 ±7 Days) ..................................................................44 
11.9 
Treatment Visit: Visit 9 (Week 36 ±7 Days) ..................................................................44 
11.10 Treatment Visit: Visit 10 (Week 42 ±7 Days) ................................................................45 
11.11 Treatment Visit: Visit 11 (Week 48 ±7 Days) ................................................................45 
11.12 Final Visit: Visit 12 (Week 52 + 10 Days) ......................................................................46 
11.13 Discontinuation Visit .......................................................................................................46 
11.14 Unscheduled Visit.............................................................................................................46 
11.15 Follow-Up Visit.................................................................................................................47 
12 Study Procedures and Assessments ....................................................................................47 
12.1 
Demography and Other Pretreatment Assessments .....................................................47 
12.2 
Efficacy Assessments .......................................................................................................47 
12.2.1 
Subject-Reported Nasal Symptoms ..........................................................................47 
12.2.2 
Physician Assessment of Nasal Symptom Severity .................................................48 
12.2.3 
Rhinoconjunctivitis Quality of Life Questionnaire - Standardized 
Activities......................................................................................................................48 
12.2.4 
Rhinitis Control Assessment Test .............................................................................49 
12.3 
Pharmacokinetic, Pharmacodynamic, Biomarker and Pharmacogenomic 
Assessments ......................................................................................................................49 
12.4 
Safety Assessments ...........................................................................................................49 
12.4.1 
Adverse Events ...........................................................................................................49 
12.4.1.1 
Adverse Events .....................................................................................................50 
12.4.1.2 
Assessment of Severity of Adverse Events .........................................................50 
12.4.1.3 
Assessment of Relationship to Study Medication .............................................51 
12.4.2 
Serious Adverse Events .............................................................................................51 
12.4.3 
Pregnancy ...................................................................................................................53 
12.4.4 
Adverse Events of Special Interest ...........................................................................53 
12.4.5 
Collection and Recording of Adverse Events and Serious Adverse Events .........53 
12.4.6 
Clinical Laboratory Tests..........................................................................................54 
12.4.7 
Urine Pregnancy Testing ...........................................................................................54 
12.4.8 
Vital signs ....................................................................................................................55 
12.4.9 
Electrocardiograms....................................................................................................55 
12.4.10 
Physical Examinations ...............................................................................................55 
12.4.11 
Focused Ears, Nose, and Throat and Eye Examinations .......................................55 
12.4.12 
Confirmation of Medical Care by Another Physician ............................................56 
Glenmark  
CONFIDENTIAL 
Page 3 of 91 

GSP 301-303 
GPL/CT/2014/018/III  
Version 2.0 
 
Date 31-Aug-2016 
13 Data Analysis and Statistical Methods ...............................................................................57 
13.1 
Sample Size .......................................................................................................................57 
13.2 
Analysis Sets .....................................................................................................................57 
13.3 
Subject Disposition...........................................................................................................57 
13.4 
Demographic and Other Baseline Characteristics ........................................................58 
13.5 
Efficacy Analyses .............................................................................................................58 
13.6 
Pharmacokinetic, Pharmacodynamic, Biomarker, and 
Pharmacogenomic/Pharmacogenetic Analyses .............................................................58 
13.7 
Safety Analyses .................................................................................................................59 
13.7.1 
Extent of Exposure .....................................................................................................59 
13.7.2 
Adverse Events ...........................................................................................................59 
13.7.3 
Laboratory Data.........................................................................................................59 
13.7.4 
Vital Signs ...................................................................................................................60 
13.7.5 
Electrocardiograms....................................................................................................60 
13.7.6 
Physical Examinations ...............................................................................................60 
13.7.7 
Focused Ears, Nose, and Throat and Eye Examinations .......................................60 
13.7.8 
Concomitant Medication and Withdrawals ............................................................60 
13.8 
Interim Analysis ...............................................................................................................60 
14 Quality Control and Quality Assurance .............................................................................60 
14.1 
Procedures for Monitoring Compliance ........................................................................61 
14.2 
Inspection ..........................................................................................................................61 
14.3 
Audit ..................................................................................................................................61 
15 Ethics ......................................................................................................................................61 
15.1 
Ethics Committee Approval ............................................................................................61 
15.2 
Ethical Conduct of the Study ..........................................................................................62 
15.3 
Informed Consent/Assent Process ..................................................................................62 
15.4 
Approval of the Protocol and Amendments ..................................................................63 
15.5 
Protocol Deviation ............................................................................................................63 
16 Data Handling and Record Keeping ...................................................................................63 
16.1 
Data Management ............................................................................................................63 
16.2 
Direct Access to Source Data/Documents ......................................................................64 
16.3 
Confidentiality and Intellectual Property ......................................................................64 
16.4 
Record Retention .............................................................................................................65 
17 Financing and Insurance ......................................................................................................65 
18 Publication Policy .................................................................................................................65 
19 Discontinuation of Study ......................................................................................................65 
20 References ..............................................................................................................................66 
21 Appendices.............................................................................................................................68 
21.1 
Appendix 1: Schedule of Procedures and Assessments ................................................69 
21.2 
Appendix 2: Subject Instructions for Proper Use of Nasal Spray Bottle ...................74 
21.3 
Appendix 3 List of Clinical Laboratory Tests ...............................................................76 
21.4 
Appendix 4: Rhinoconjunctivitis Quality-Of-Life Questionnaire with 
Standardized Activities ....................................................................................................77 
21.5 
Appendix 5: Rhinitis Control Assessment Test .............................................................83 
21.6 
Appendix 6: List of Contact Details ...............................................................................87 
21.7 
Appendix 7: GSP 301-303 Protocol Amendment 1.0 ....................................................88 
Glenmark  
CONFIDENTIAL 
Page 4 of 91 

GSP 301-303 
GPL/CT/2014/018/III  
Version 2.0 
 
Date 31-Aug-2016 
 
 
LIST OF FIGURES 
Figure 1: Study Design Schematic ..................................................................................25 
 
LIST OF APPENDICES 
21.1 Appendix 1: Schedule of Procedures and Assessments .........................................69 
21.2 Appendix 2: Subject Instructions for Proper Use of Nasal Spray Bottle ............74 
21.3 Appendix 3 List of Clinical Laboratory Tests ........................................................76 
21.4 Appendix 4: Rhinoconjunctivitis Quality-Of-Life Questionnaire with 
Standardized Activities ............................................................................................77 
21.5 Appendix 5: Rhinitis Control Assessment Test ......................................................83 
21.6 Appendix 6: List of Contact Details ........................................................................87 
21.7 Appendix 7: GSP 301-303 Protocol Amendment 1.0 .............................................88 
 
 
Glenmark  
CONFIDENTIAL 
Page 5 of 91 

GSP 301-303 
GPL/CT/2014/018/III  
Version 2.0 
 
Date 31-Aug-2016 
1 ABBREVIATIONS AND SPECIALIST TERMS 
Abbreviation 
Definition or Explanation 
AE 
Adverse event 
AM 
Morning 
ANCOVA 
Analysis of covariance 
AR 
Allergic rhinitis 
β-HCG 
beta human chorionic gonadotropin 
BID 
Twice daily 
oC 
Degrees Celsius 
CFR 
Code of Federal Regulations (of the United States) 
CI 
Confidence interval 
CRF 
Case report form 
CRO 
Contract research organization 
CSR 
Clinical study report 
CYP3A4 
Cytochrome P450 system enzyme 3A4 
DV 
Discontinuation visit 
ECG 
Electrocardiogram 
eCRF 
Electronic case report form 
ENT 
Ears, nose, and throat 
EOP2 
End-of-Phase 2 
oF 
Degrees Fahrenheit 
FAS 
Full Analysis Set 
FcεRI  
IgE receptor 
FDA 
Food and Drug Administration (of the United States) 
FDC 
Fixed dose combination 
FV 
Final visit 
GCP 
Good Clinical Practice 
GMP 
Good Manufacturing Practice 
GRAS 
Generally regarded as safe 
GSP 301 NS 
Fixed dose combination of olopatadine hydrochloride and mometasone furoate 
nasal spray 
HIPAA 
Health Insurance Portability and Accountability Act 
HIV 
Human immunodeficiency virus 
IB 
Investigator’s Brochure 
ICF 
Informed consent form 
ICH 
International Conference on Harmonisation 
IEC 
Independent Ethics Committee 
IgE 
Immunoglobulin E 
IL 
Interleukin 
IND 
Investigational New Drug 
IP  
Investigational product 
IRB 
Institutional Review Board 
iTNSS 
instantaneous Total Nasal Symptom Score 
IUD 
Intrauterine device 
LAR 
Legally acceptable representative 
LASIK 
Laser-assisted in situ keratomileusis 
LSM 
Least squares mean 
µg 
microgram 
Glenmark  
CONFIDENTIAL 
Page 6 of 91 

GSP 301-303 
GPL/CT/2014/018/III  
Version 2.0 
 
Date 31-Aug-2016 
 
 
 
 
MedDRA 
Medical Dictionary for Regulatory Activities 
NS 
Nasal spray 
OTC 
Over-the-counter 
PAR 
Perennial allergic rhinitis 
PM 
Evening 
PNSS 
Physician assessed Nasal Symptom Score 
PPS 
Per protocol set 
PT 
Preferred term 
QD 
Once daily 
QOL 
Quality of life 
RAST 
Radioallergosorbent test 
RCAT 
Rhinitis Control Assessment Test 
RQLQ(S) 
Rhinoconjunctivitis Quality of Life Questionnaire - Standardized Activities 
rTNSS 
reflective Total Nasal Symptom Score 
RV 
Randomization visit 
SAE 
Serious adverse event 
SAP 
Statistical analysis plan 
SAR 
Seasonal allergic rhinitis  
SAS 
Safety analysis set 
SD 
Standard deviation 
SOC 
System organ class 
SOP 
Standard operating procedure 
SV 
Screening visit 
TEAE 
Treatment-emergent adverse event 
TNSS 
Total Nasal Symptom Score 
TV 
Treatment visit 
US 
United States 
USPI 
United States Prescribing Information 
Glenmark  
CONFIDENTIAL 
Page 7 of 91 

GSP 301-303 
GPL/CT/2014/018/III  
Version 2.0 
 
Date 31-Aug-2016 
2 PROTOCOL SYNOPSIS 
Name of Sponsor/Company: Glenmark Specialty S.A. 
Protocol Title: A Double-Blind, Randomized, Parallel-Group Study to Evaluate Long-Term Safety, Tolerability, 
and Efficacy of a Fixed Dose Combination GSP 301 Nasal Spray Compared with Two Placebo Nasal Spray 
Formulations in Subjects (Aged 12 Years and Older) with Perennial Allergic Rhinitis (PAR) 
Protocol Number: GPL/CT/2014/018/III 
Study Number: GSP 301-303 
Name of Investigational Product(s)/Code(s) 
• 
GSP 301 nasal spray (GSP 301 NS): olopatadine hydrochloride 665 μg and mometasone furoate 25 μg 
nasal spray (NS) 
• 
GSP 301 placebo NS pH 
• 
GSP 301 placebo NS pH 
Name of Active Ingredient: Olopatadine hydrochloride and mometasone furoate  
Phase of Development: Phase 3 
Study Rationale 
The ideal therapeutic agent for managing the symptoms of allergic rhinitis (AR) is one that effectively addresses the 
pathophysiology of both the early-phase reaction and the late-phase reaction of the condition.20 Published studies 
have indicated that taking both intranasal antihistamine and corticosteroid are more beneficial than either medication 
alone in the treatment of seasonal allergic rhinitis (SAR).21 
Olopatadine hydrochloride has been shown to be clinically superior to other anti-allergy molecules because of its 
strong antihistamine activity and unique ocular mast cell stabilizing properties.1 Olopatadine hydrochloride NS has 
been approved in the United States (US) as Patanase® NS for the relief of the symptoms of SAR in adults (in 2008, 
as 2 sprays per nostril twice daily [BID]; total daily dose of 5320 µg) and in children 6 years of age or older (in 
2009, as 1 spray per nostril BID). The efficacy and safety data from adult, adolescent, and pediatric subjects in 
clinical studies of Patanase® NS are provided in the US Prescribing Information (USPI).9  
Mometasone furoate NS (Nasonex® NS, 50 µg/spray) has been approved in the US for the treatment of nasal 
symptoms of AR in patients aged 12 years and older as 2 sprays in each nostril once daily (QD) (200 µg total daily 
dose) and as 1 spray per nostril QD (100 µg total daily dose) for children aged 2 to 11 years. Other indications 
include treatment of nasal congestion associated with SAR in patients aged 2 years or older; prophylaxis of SAR in 
patients aged 12 years or older, and treatment of nasal polyps in adults. The efficacy and safety data from adult, 
adolescent, and pediatric subjects in clinical studies of Nasonex® NS are provided in the USPI.10 
 Currently, only 1 combination product containing an intranasal 
corticosteroid and intranasal antihistamine is available for SAR treatment (Dymista USPI),15 but no such option is 
available for patients suffering from PAR in the US. Based on the results from a Phase 2 study conducted with 
GSP 301 (Study GSP 301-201), 
 (olopatadine hydrochloride 665 μg and 
mometasone furoate 25 μg) was found to be op ma y safe and effective for the treatment of SAR in adult and 
adolescents and will be further evaluated in the Phase 3 studies. 
The primary objective of the present study is to evaluate the long-term safety and tolerability of GSP 301 NS 
administered as
 compared with 2 different formulations of GSP 301 placebo NS formulations 
that differ in pH. The secondary objective is to evaluate the long-term efficacy of GSP 301 NS compared with 
GSP 301 placebo NS pH 
. 
For this study, the subject population will be adult and adolescent subjects (aged ≥12 years) with PAR. The subjects 
will be asked to take their daily double-blind, study medication for a period of 52 weeks following a 7 to 10 day, 
single-blind, placebo run-in period. 
Glenmark  
CONFIDENTIAL 
Page 8 of 91 

GSP 301-303 
GPL/CT/2014/018/III  
Version 2.0 
 
Date 31-Aug-2016 
Study Objectives  
Primary Objective:  
• To compare the long-term safety and tolerability of GSP 301 NS with 2 GSP 301 placebo NS formulations over 
52 weeks of study treatment.  
Secondary Objective: 
• 
To evaluate the long-term efficacy of GSP 301 NS compared with GSP 301 placebo NS
 in subjects with 
PAR. 
Planned Number of Subjects: Approximately 600 randomized subjects in a ratio of 4:1:1 (400 subjects in the 
GSP 301 NS group and 100 subjects in each of the 2 placebo groups) are planned for this study. 
Planned Duration of Subject Participation: Subject participation may extend up to 55 weeks with up to 7 to 
10 days of a screening/run-in period and a 52-week treatment period, with allowable window periods for the study 
visits. 
Inclusion Criteria: Subjects eligible for enrolment in the study must meet all of the following criteria: 
1. Males and non-pregnant females aged ≥12 years. 
2. Signed informed consent/assent form (subject and/or parent/caregiver/legal guardian) that meets all criteria of 
the current US Food and Drug Administration (FDA)/local regulations. 
3. Documented clinical history of PAR (for at least 2 years preceding the Screening Visit [Visit 1]) with 
exacerbations (clinical evidence of active symptoms) and exhibiting a documented positive skin prick test (wheal 
diameter at least 3 mm greater than negative diluent control wheal) to at least 1 allergen known to induce PAR. 
Documentation of a positive result within 12 months prior to the Screening Visit (Visit 1) is acceptable. 
Additionally, the subject is expected to be exposed to the PAR allergen that he/she tested positive for via the skin 
prick test for the entire duration of the study. 
4. General good health and free of any disease or concomitant treatment that could interfere with the interpretation 
of study results as determined by the Investigator. 
5. Subjects must be able to demonstrate the correct NS application technique at the Screening Visit (Visit 1). 
6. Subjects must be willing and able to comply with all aspects of the protocol. 
Exclusion Criteria: Subjects meeting any of the following criteria must not be enrolled in the study:    
1. Have a positive pregnancy test or established pregnancy, breast-feeding, or planning a pregnancy during the 
study. 
2. Female subjects of child-bearing potential (as judged by the Investigator) who do not agree to remain abstinent 
or use medically acceptable methods of contraception (e.g., implants, injectables, combined oral contraceptives, 
intrauterine devices [IUDs], double-barrier protection) during the study. Male participants who do not agree to 
use a condom with spermicide during intercourse (if not surgically sterilized) during the study. 
3. History of significant atopic dermatitis or rhinitis medicamentosa (within 60 days prior to the Screening Visit 
[Visit 1]). 
4. Treatment with any known potent CYP3A4 inducers (carbamazepine, dexamethasone, phenytoin, rifabutin, 
rifampin, pioglitazone, etc.) or potent inhibitors (azole antifungals, macrolide antibiotics, etc.) within 30 days 
prior to or during the study. 
5. Non-vaccinated exposure to or active infection with chickenpox or measles within 21 days preceding the 
Screening Visit (Visit 1). 
6. Known hypersensitivity to any corticosteroids or antihistamines or to the study medication or its excipients. 
7. History of anaphylaxis and/or other severe local reaction(s) to skin testing. 
Glenmark  
CONFIDENTIAL 
Page 9 of 91 

GSP 301-303 
GPL/CT/2014/018/III  
Version 2.0 
 
Date 31-Aug-2016 
8. History of alcohol or drug dependence within 2 years preceding the Screening Visit (Visit 1). 
9. History of a positive test for human immunodeficiency virus (HIV), Hepatitis B, or Hepatitis C infection. 
10. Evidence of acute or significant chronic sinusitis or chronic purulent postnasal drip. 
11. Any of the following conditions (including but not limited to the following) that are judged by the Investigator 
to be clinically significant and/or to affect the subject’s ability to participate in this study: 
o 
Impaired hepatic function including alcohol-related liver disease or cirrhosis 
o 
Any systemic infection 
o 
Hematological, hepatic, renal, endocrine disorder (except for postmenopausal symptoms or 
hypothyroidism) 
o 
Gastrointestinal disease 
o 
Malignancy (excluding basal cell carcinoma) 
o 
Current neuropsychological condition with or without drug therapy 
o 
Cardiovascular disease (e.g., uncontrolled hypertension) 
o 
Respiratory disease other than mild asthma 
12. Any major surgery (as assessed by the Investigator) within 4 weeks preceding the Screening Visit (Visit 1). 
13. Requirement for the chronic use of tricyclic anti-depressants. 
14. Dependence (in the opinion of the Investigator) on nasal, oral, or ocular decongestants, nasal topical 
antihistamines, or nasal steroids. 
15. Active pulmonary disorder or infection (including but not limited to bronchitis, pneumonia, or influenza), or 
upper respiratory tract or sinus infection within the 14 days prior to the Screening Visit (Visit 1) or the 
development of respiratory infections during the run-in period. Subjects with mild asthma are allowable on the 
condition that treatment is limited to inhaled short-acting beta-agonists only (up to 8 puffs per day). 
16. Use of antibiotic therapy for acute conditions within 14 days prior to the Screening Visit (Visit 1). Low doses of 
antibiotics taken for prophylaxis are allowed if the therapy was started prior to the Screening Visit (Visit 1) and 
is expected to continue at the same stable dose throughout the clinical study duration. 
17. Posterior subcapsular cataracts or glaucoma, or any other ocular disturbances, or other listed related conditions 
including: 
o 
History of increased intraocular pressure 
o 
History of retinal detachment or surgery 
o 
History of incisional eye surgery (other than cataract extraction or laser-assisted in situ keratomileusis 
[LASIK]) 
o 
History of penetrating ocular trauma or severe blunt ocular trauma 
o 
Evidence of uveitis, iritis, or other inflammatory eye disease during screening 
o 
Presence of ocular herpes simplex 
18. Known history of hypothalamic-pituitary-adrenal axis impairment.  
19. Existence of any significant surgical or medical condition, or clinically significant physical finding (e.g. 
significant nasal polyps or other clinically significant respiratory tract malformations/nasal structural 
abnormalities, significant nasal trauma [such as nasal piercing] or significant nasal septal deviation) which, in 
the opinion of the Investigator or Sponsor’s medical monitor, significantly interferes with the absorption, 
Glenmark  
CONFIDENTIAL 
Page 10 of 91 

GSP 301-303 
GPL/CT/2014/018/III  
Version 2.0 
 
Date 31-Aug-2016 
distribution, metabolism or excretion of the study medication or significantly interferes with nasal air flow or 
interferes with the subject’s ability to complete or reliably complete the AR Assessment Diary. 
20. Participation in any investigational non-biological drug clinical study in the 30 days or investigational 
biological drug in the 120 days preceding the Screening Visit (Visit 1) or planned participation in another 
investigational clinical study at any time during the current study. 
21. Initiation of immunotherapy injections or immunosuppressive/immune-modulator medications (except topical 
pimecrolimus cream or tacrolimus ointment if initiated at least 30 days prior to screening and maintained on 
stable dose) within 60 days preceding the Screening Visit (Visit 1). A 180-day washout period is required 
following the last dose of sublingual immunotherapy (investigational or other) prior to the Screening Visit 
(Visit 1).   
22. Use of topical corticosteroids in concentrations in excess of 1% hydrocortisone or equivalent within 30 days 
prior to the Screening Visit (Visit 1); use of a topical hydrocortisone or equivalent in any concentration 
covering greater than 20% of the body surface; or the presence of an underlying condition (as judged by the 
Investigator) that can reasonably be expected to require treatment with such preparations during the clinical 
study duration. 
23. Study participation by clinical investigational site employees and/or their immediate relatives. 
24. Study participation by more than 1 subject from the same household at the same time. However, after 
completion/discontinuation by 1 subject in the household, another subject from the same household may be 
screened. 
25. Known to have failed to show symptom improvement with any approved/marketed monotherapy component of 
GSP 301 NS (i.e., Nasonex® NS or Patanase® NS or both) as judged by the Investigator. 
26. Previous participation in a GSP 301 NS study as a randomized subject.  
Randomization Criteria: 
1. Continued general good health meeting the Screening inclusion criteria. 
2. Has not experienced an adverse event (AE) that would result in not meeting the Screening inclusion criteria. 
3. Minimum morning (AM) subject-reported reflective Total Nasal Symptom Score (rTNSS) of an average of 5 
(out of a possible 12) during the last 4 days of the run-in period (last 4 consecutive AM assessments from the 
Day -3 AM assessment to the AM assessment on the day of randomization).  
4. Has an AM subject-reported reflective nasal congestion score ≥2 during the last 4 days of the run-in period (last 
4 consecutive AM assessments from the Day -3 AM assessment to the AM assessment on the day of 
randomization).  
5. Adequate AR Assessment Diary compliance – inadequate compliance is defined as missing 1 or more of the 
entries on 2 or more assessment sessions (AM) during the last 4 days of the run-in period (during the last 
4 consecutive AM assessments from the Day -3 AM assessment to the AM assessment on the day of 
randomization). 
6. Adequate study medication compliance – each subject must have taken his/her single-blind medication for at 
least 80% of the entire run-in period as reported in the AR Assessment Diary. 
7. Has not suffered from the common cold, upper respiratory infections, otitis media, lower respiratory infections, 
or acute sinusitis within the 14 days prior to the Randomization Visit (Visit 2). 
8. Has not used any of the prohibited concomitant medications during the run-in period. 
Study-Specific Discontinuation/Withdrawal Criteria  
A subject may voluntarily discontinue study participation at any time after giving informed consent and before the 
completion of the last visit of the study. The Investigator may also discontinue the subject’s study participation at 
any time at his/her discretion and for any reason.  
The reasons for subject withdrawal will be recorded and may include, but are not limited to: 
1. Withdrawal of consent by the subject to continue in the study. 
2. Development of a serious or intolerable AE that necessitates discontinuation at the discretion of the Investigator 
Glenmark  
CONFIDENTIAL 
Page 11 of 91 

GSP 301-303 
GPL/CT/2014/018/III  
Version 2.0 
 
Date 31-Aug-2016 
(AE section of the case report form/electronic case report form [CRF/eCRF] must be completed; includes 
serious adverse event [SAE], death). 
3. At the discretion of the Investigator, when he/she believes continued participation is not in the best interest of 
the subject. 
4. At the discretion of the Investigator, when the subject does not adhere to the study procedures. 
5. A protocol deviation that, in the opinion of the Sponsor and Investigator, warrants discontinuation from the 
study. 
Lifestyle and/or Dietary Restrictions: Not applicable. 
Investigational Products, Dose, and Mode of Administration  
Name of Investigational Product: Fixed dose combination (FDC) of olopatadine hydrochloride 665 µg and 
mometasone furoate 25 µg NS (GSP 301 NS) 
License Name: GSP 301-2 NS 
Dosage Form: NS 
Dosage: 
 
Dosage Frequency: 
 
Mode of Administration: Intranasal 
 
Reference Product 1: GSP 301 Placebo NS 
License Name: GSP 301 Placebo NS 
 
Dosage Form: NS 
Dosage: 2
 
Dosage Frequency: 
  
Mode of Administration: Intranasal 
 
Reference Product 2: GSP 301 Placebo NS 
 
License Name: GSP 301 Placebo NS 
 
Dosage Form: NS 
Dosage: 
 
Dosage Frequency: 
  
Mode of Administration: Intranasal 
 
Duration of Treatment: 52 weeks  
Prior and Concomitant Drug/Therapy 
Exclusion of Medication Prior to the Screening Visit (Visit 1): 
1. 
Vasoconstrictors (e.g., epinephrine, sumatriptan) 
3 days 
2. 
Major tranquilizers (e.g., antipsychotics such as chlorpromazine, haloperidol, risperadol, 
clonazepam) 
3 days 
3. 
Short-acting antihistamines (oral, ocular, or intranasal antihistaminic – e.g., azelastine)  
7 days 
4. 
Over-the-counter (OTC) cough and cold preparations or sleep aids containing antihistamines  
7 days 
5. 
Topical/oral/nasal decongestants (e.g., oxymetazoline, pseudoephedrine, tetrahydrozoline)  
7 days 
6. 
OTC food supplement/diet to reduce leukotrienes (Airozin) 
7 days 
7. 
Leukotriene antagonists or arachidonate 5-lipoxygenase inhibitors 
7 days 
8. 
Inhaled/oral/intranasal anticholinergics 
7 days 
9. 
Long-acting antihistamines (e.g., cetirizine, fexofenadine) 
10 days 
Glenmark  
CONFIDENTIAL 
Page 12 of 91 

GSP 301-303 
GPL/CT/2014/018/III  
Version 2.0 
 
Date 31-Aug-2016 
10. Cromolyn (all forms), nedocromil, or lodoxamide (intranasal, ocular, or oral)   
14 days 
11. Systemic antibiotic (see excluded concomitant medications) 
14 days 
12. Ocular mast cell stabilizers 
14 days 
13. Monoamine oxidase inhibitors 
14 days 
14. Tricyclic antidepressants 
14 days 
15. All intranasal/topical/ocular corticosteroids (except study medication) 
30 days 
16. Inhaled corticosteroids 
30 days 
17. Any other investigational non-biological drug 
30 days 
18. Treatment with any known potent CYP3A4 inducers (carbamazepine, dexamethasone, 
phenytoin, rifabutin, rifampin, pioglitazone, etc.) 
30 days 
19. Treatment with any known potent CYP3A4 inhibitors (azole antifungals, macrolide antibiotics, 
etc.) 
30 days 
20. Systemic corticosteroids (intermittent or chronic including intra-articular) 
60 days 
21. Immunotherapy injections and immunosuppressive/immune-modulator medications (except 
topical pimecrolimus cream or tacrolimus ointment if initiated at least 30 days prior to screening 
and maintained on stable dose) 
60 days 
22. Immunoglobulin E (IgE) antagonist or any other anti-IgE therapy 
120 days 
23. Any other investigational biological drug. 
120 days 
24. Anti-interleukin-5 (anti-IL-5) therapy (e.g., reslizumab, mepolizumab, etc.) 
120 days 
25. Sublingual immunotherapy (investigational or other) 
180 days 
These above medications are also prohibited throughout the entire study except for rescue medications (see Rescue 
Medication text). In addition, the following medications are prohibited throughout the entire study: 
1. 
All intranasal therapies (including saline) other than study medication 
2. 
Topical corticosteroids (except for the treatment of small, localized lesions) 
3. 
Radiation therapy 
4. 
Initiation of immunotherapy 
5. 
Any investigational drug being used in another clinical study 
6. 
Herbal medications/supplements to treat AR, or any other alternative therapies to treat AR 
7. 
St. John’s Wort (Hypericum perforatum) 
8. 
Guaifenesin-containing products (e.g., Mucinex) 
Excluded Concomitant Medications: 
1. No asthma preventive medication will be permitted during the study except for inhaled short-acting beta-
agonists for mild asthma (up to 8 puffs per day). 
2. Subjects can receive topical immunotherapy (e.g., pimecrolimus cream or tacrolimus ointment), provided 
Glenmark  
CONFIDENTIAL 
Page 13 of 91 

GSP 301-303 
GPL/CT/2014/018/III  
Version 2.0 
 
Date 31-Aug-2016 
initiation of topical immunotherapy was at least 30 days prior to the Screening Visit (Visit 1) and the subject 
uses a stable maintenance dose (30 days or more) prior to the Screening Visit (Visit 1) as well as during the 
study. 
3. Potent CYP3A4 inhibitors (such as ketoconazole, itraconazole, erythromycin) and potent CYP3A4 inducers 
(such as carbamazepine, dexamethasone, phenytoin, rifabutin, rifampin, pioglitazone) are prohibited 30 days 
prior to the Screening Visit (Visit 1) as well as during the study. 
4. Use of antibiotic therapy for acute conditions within 14 days prior to the Screening Visit (Visit 1). Low doses 
of antibiotics taken for prophylaxis are allowed if the therapy was started prior to the Screening Visit 
(Visit 1) and is expected to continue at the same stable dose throughout the clinical study duration. 
Rescue Medications: 
The following rescue medication, non-nasal formulations only, is allowed in the study ONLY after Treatment 
Visit 4 (Week 6): 
• 
Loratadine (10 mg/day) 
The use of rescue medications will be available only after the first 6 weeks of treatment (after Treatment Visit 4). 
No rescue medication will be provided or allowed during the placebo run-in period or prior to Day 43 of the 
treatment period. Subjects should be instructed that rescue medication use should be minimal and used only as 
needed when the subject’s symptoms are intolerable. Additional rescue medication should be prescribed only if 
the provided rescue medication (loratadine 10 mg/day) is not effective in relieving the symptoms as judged by the 
Investigator (e.g. topical/oral decongestants [e.g., oxymetazoline, pseudoephedrine, tetrahydrozoline], short-
acting ocular antihistamines, long-acting antihistamines [e.g., desloratadine, cetirizine, fexofenadine], OTC cough 
and cold preparations or sleep aids containing antihistamines). Once the symptoms are deemed to be under 
control, rescue medication usage should be minimized or discontinued. Rescue medications should be used as 
prescribed by the Investigator/designee at approved dosages as applicable per the prescribing information of the 
medication. 
Permitted Medications: 
With the exception of medications listed as excluded, subjects will be allowed to use other chronic medications at 
stable doses and other medications at the discretion of the Investigator (in consultation with the Sponsor) as long 
as they do not interfere with the safety and efficacy variables of the study. 
Endpoints   
Primary Endpoints 
• 
Proportion of subjects with treatment-emergent adverse events (TEAEs).   
• 
Proportion of subjects with treatment-related TEAEs. 
• 
Incidence, type, and severity of the TEAEs after 30 weeks of study treatment. 
• 
Incidence, type, and severity of the TEAEs after 52 weeks of study treatment.  
• 
Clinical laboratory assessments (hematology, serum biochemistry, and urinalysis) at baseline, Week 30, 
and Week 52. 
• 
Vital signs, physical examinations (PE), and focused ears, nose, and throat (ENT) and eye examinations at 
baseline, Week 30, and Week 52. 
Secondary Endpoints 
Efficacy Endpoints 
• 
Change from baseline in the average AM subject-reported rTNSS over the first 6, 30, and 52 weeks of 
Glenmark  
CONFIDENTIAL 
Page 14 of 91 

GSP 301-303 
GPL/CT/2014/018/III  
Version 2.0 
 
Date 31-Aug-2016 
treatment.  
• 
Change from baseline in the average AM subject-reported instantaneous Total Nasal Symptom Score 
(iTNSS) over the first 6, 30, and 52 weeks of treatment. 
• 
Change from baseline in the overall Rhinoconjunctivitis Quality of Life Questionnaire – Standardized 
Activities (RQLQ(S)) score at Weeks 6, 30, and 52 for the Full Analysis Set (FAS). 
Other Efficacy Endpoints 
Nasal symptoms: 
• 
Change from baseline in the average AM subject-reported reflective individual nasal symptoms over the 
first 6, 30, and 52 weeks of treatment.  
• 
Change from baseline in the average AM subject-reported instantaneous individual nasal symptoms over 
the first 6, 30, and 52 weeks of treatment.  
• 
Change in the average AM subject-reported rTNSS and iTNSS from baseline to the end of each treatment 
week. 
• 
Change in the average AM subject-reported reflective individual nasal symptoms from baseline to the end 
of each treatment week.  
• 
Change in the average AM subject-reported instantaneous individual nasal symptoms from baseline to the 
end of each treatment week. 
 
Physician assessed Nasal Symptom Score (PNSS), Rhinoconjunctivitis Quality of Life Questionnaire – 
Standardized Activities (RQLQ(S)), and Rhinitis Control Assessment Test (RCAT): 
• 
Change from baseline in PNSS and physician assessed individual nasal symptoms at Weeks 6, 30, and 52. 
• 
Change from baseline in individual domains of the RQLQ(S) at Weeks 6, 30, and 52 for the FAS. 
• 
Change from baseline in overall RQLQ(S) score and individual domains of the RQLQ(S) at Weeks 6, 30, 
and 52 for the RQLQ(S) Analysis Set. 
• 
Change from baseline in the RCAT at Weeks 6, 30, and 52. 
• 
Change from baseline in individual domains of the RCAT at Weeks 6, 30, and 52. 
 
Exploratory Endpoints: 
Not applicable 
 
Pharmacokinetic, Pharmacodynamic, Biomarker, and Pharmacogenomic Assessments 
Pharmacokinetic Assessments 
Not applicable. 
Pharmacodynamic Assessments 
Not applicable. 
Biomarker Assessments 
Not applicable. 
Pharmacogenomic Assessments 
Not applicable. 
Bioanalytical Methods: Not Applicable 
Statistical Methods  
The FAS will consist of all subjects who are randomized and receive at least 1 dose of investigational product (IP) 
and have at least 1 post-baseline efficacy assessment. This will be the primary analysis set for efficacy analyses.  
The Per Protocol Set (PPS) will consist of the subset of the FAS who do not meet criteria for PPS exclusion. 
The Safety Analysis Set (SAS) will consist of all subjects who took at least 1 dose of study medication following 
randomization and will be used for all safety analyses. 
The RQLQ(S) Analysis Set will consist of all English-speaking subjects ≥18 years old with impaired quality of life 
(QOL) at baseline as defined by a RQLQ(S) score at the Randomization Visit (Visit 2) of 3.0 or greater. 
Determination of Sample Size  
The sample size of 600 subjects for this study (400 subjects on GSP 301 NS and 100 subjects in each of the 
2 placebo groups) is based on the International Conference on Harmonisation (ICH) Guideline E119 and the FDA 
Guidance on Allergic Rhinitis,14 which requires treatment of at least 300 subjects for 6 months and 100 subjects for 
Glenmark  
CONFIDENTIAL 
Page 15 of 91 

GSP 301-303 
GPL/CT/2014/018/III  
Version 2.0 
 
Date 31-Aug-2016 
1 year. Based on an estimated attrition rate of 25% at the 6 month time point and 50% by 52 weeks, 400 subjects in 
the GSP 301 NS treatment group are considered sufficient to meet the above requirements. 
 
Efficacy Analyses 
Change from baseline in average AM subject-reported rTNSS and iTNSS over the first 6, 30, and 52 weeks of 
treatment will be analyzed using an analysis of covariance (ANCOVA) model adjusting for study treatment group, 
site, and baseline (defined as the average of the last 4 consecutive AM assessments during the last 4 days of the 
run-in period from the Day -3 AM assessment to the AM assessment on the day of randomization). At least 2 out of 
4 assessments (scores) should be available in order to calculate the baseline scores for the AM rTNSS and iTNSS 
(linear, continuous covariate). Least square means (LSMs) of the treatment differences and associated 95% 
confidence intervals (95% CIs) and p-values will be presented. A multiple, imputation-based approach where 
complete data sets are drawn will be used for handling missing data in the efficacy analysis. The imputation model 
will be defined and fully detailed in the statistical analysis plan (SAP). 
Changes from baseline in rTNSS and iTNSS at the end of each week of treatment and changes from baseline in 
individual nasal symptom scores over the first 6, 30, and 52 weeks (and at the end of each treatment week) of the 
treatment period will be analyzed in a similar manner as described above.  
Changes from baseline in RQLQ(S) at Weeks 6, 30, and 52 will be analyzed for the FAS and the RQLQ(S) Analysis 
Set using ANCOVA models adjusting for study treatment group, site, and baseline RQLQ(S) (linear, continuous 
covariate). For subjects who withdrew early from the study, the RQLQ(S) score at their discontinuation visit will be 
used. 
The analyses of RCAT results will be similar to the RQLQ(S) analyses except the RQLQ(S) analysis set will not 
apply. 
Detailed statistical analysis and methods will be provided in the SAP. 
Pharmacokinetic, Pharmacodynamic, Pharmacogenomic, and Other Biomarker Analyses: Not applicable. 
 
Safety Analyses 
Adverse events (including TEAEs) will be classified using the current version of the Medical Dictionary for 
Regulatory Activities (MedDRA) and summarized by treatment group. Summary tables comparing the type, 
incidence, severity and drug relationship will be presented by treatment group. If sufficient data exist, TEAE 
frequencies will be compared across treatment groups using Fisher’s exact test or a similar test.  
Detailed statistical analysis and methods will be provided in the SAP.  
 
Interim Analyses: No interim analysis is planned for the study. 
 
 
Glenmark  
CONFIDENTIAL 
Page 16 of 91 

GSP 301-303 
GPL/CT/2014/018/III  
Version 2.0 
 
Date 31-Aug-2016 
3 INVESTIGATOR’S SIGNATURE  
• I have reviewed the clinical protocol.  
• I have fully discussed the objective(s) of this study and the contents of this protocol with the 
Sponsor’s representative.  
• I understand that the information in this protocol is confidential and should not be disclosed, 
other than to those directly involved in the execution or the scientific/ethical review of the 
study, without written authorization from the Sponsor. It is, however, permissible to provide 
the information contained herein to a subject in order to obtain their consent to participate.  
• I agree to conduct this study according to this protocol and to comply with its requirements, 
subject to ethical and safety considerations and guidelines, and to conduct the study in 
accordance with International Conference on Harmonisation (ICH) guidelines on Good 
Clinical Practice (GCP), and with the applicable regulatory requirements.  
• I understand that failure to comply with the requirements of the protocol may lead to my 
participation as an Investigator for this study to be terminated.   
• I understand that the Sponsor may decide to suspend or prematurely terminate the study at 
any time for whatever reason; such a decision will be communicated to me in writing. 
Conversely, should I decide to withdraw from execution of the study I will communicate my 
intention immediately in writing to the Sponsor.  
 
 
_________________________________ 
___________________ 
Name of Investigator, degree 
Date 
Title  
 
Address and contact details 
 
 
 
 
Glenmark  
CONFIDENTIAL 
Page 17 of 91 

GSP 301-303 
4 SPONSOR'S SIGNATURE 
G PUCT /20 14/0 J 8/111 
Version 2.0 
Date 3 J -Aug-20 16 
This protocol reflects the Sponsor's current knowledge of Fixed Dose Combination (FDC) of 
olopatadine hydrochloride and mometasone furoate nasal spray (GSP 301 NS) as applicable to 
this study. It has been designed to achieve the stated objectives whilst minimizing exposure to, 
and risk from, both the products being used and the assessments. The assessments are aH 
considered to be appropriate, capable of validating the stated objectives of the study, and of 
providing the necessary information to ensure subject safety. The protocol has been designed 
according to the principles of the International Conference on Harmonisation (ICH) guidelines 
for Good Clinical Practice (GCP), Declaration of Helsinki. It has undergone both medical and 
scientific review by the Sponsor. The Sponsor is responsible to regulatory authorities for taking 
all reasonable steps to ensure the proper conduct of the study as regards ethics, protocol 
compliance, integrity and validity of the data recorded on the case report forms/electronic case 
report forms (CRFs/eCRFs). 
• 
We hereby agree to conduct the study in accordance with this protocol and the above-
mentioned guidance/ regulation. 
• We agree to comply with all relevant standard operating procedures (SOPs) required for the 
conduct of this study. 
• We further agree to ensure that all associates assisting in the conduct of study are informed 
regarding their obligations. 
Signed on behalfofthe Sponsor, Glenmark Specialty SA. Switzerland: 
Vice President, Clinical Development 
Protocol Author 
Glenmark Phannaceuticals 
750 Corporate Drive, Mahwah, NJ 07430, USA 
E-mail: 
Fred Grossman, 
President, Clini 
R&D and CMO 
Glenmark P 
r aceuticals 
750 Corpora 
rive, Mahwah, NJ 07430, USA 
E~mail: fred.grossman
Glenmark 
CONFIDENTIAL 
31- A Ll j ~ 2.-n f6 
Date: 
Page 18 of90 

GSP 301-303 
GPL/CT/2014/018/III  
Version 2.0 
 
Date 31-Aug-2016 
5 BACKGROUND INFORMATION 
5.1 
Introduction 
Rhinitis is defined as inflammation of the nasal membranes and is characterized by the presence 
of the following: nasal congestion, rhinorrhea, sneezing, nasal itching, and nasal obstruction. 
Allergic rhinitis (AR) is the most common cause of rhinitis and represents a global health 
problem affecting approximately 10% to 30% of the general adult population and its prevalence 
is increasing worldwide.1,2 In the United States (US), it affects 10% to 30% of the adult general 
population and up to 40% of children. This accounts for 30 to 60 million people in the US. In the 
US, the direct medical costs (physician services, diagnostics, medications, etc.) nearly doubled 
from US $6.1 billion in 2000 to US $11.2 billion in 2005.1  
Allergic rhinitis has been traditionally subdivided into seasonal, perennial, and occupational 
rhinitis and involves the inflammation of the mucous membranes of the nose, eyes, eustachian 
tubes, middle ear, sinuses, and pharynx. Inflammation of the mucous membranes is characterized 
by a complex interaction of inflammatory mediators but ultimately is triggered by an 
immunoglobulin E (IgE)-mediated response to extrinsic proteins such as pollens or molds (food 
allergies rarely cause AR except as part of a multi-organ reaction).3,4,5 When 2 or more 
symptoms such as watery rhinorrhea, sneezing, nasal obstruction, and nasal pruritus persist for 
≥1 hour, AR is strongly suspected.  
After allergens are inhaled into the nasal mucosa of sensitized subjects, they bind to IgE on the 
surface of mast cells, resulting in aggregation of IgE receptors (FcεRI) and the release of 
chemical mediators including histamine. Binding of histamine to the histamine H1 receptor 
increases paracellular permeability, which contributes to the early-phase response of AR, 
characterized by sneezing, rhinorrhea, and nasal congestion. Infiltration of inflammatory cells 
(activated eosinophils and T-helper type 2 cells) into the nasal mucosa is induced by chemo-
attractant factors (including various cytokines) and results in edema of the nasal mucosa. This 
inflammation, the late-phase response of AR, develops 6 to10 hours after allergen challenge and 
causes prolonged nasal congestion.6  
Many pharmacologic agents are available to treat AR. They target different symptoms and 
include oral antihistamines, intranasal corticosteroids, intranasal antihistamines, decongestants, 
mast cell stabilizers, leukotriene modifiers, anticholinergics, and allergen immunotherapy.1,7,8 
Topical (intranasal) antihistamines (histamine H1 receptor antagonists) are prescribed to treat the 
nasal itch, sneezing, and rhinorrhea caused by the release of histamine and inflammatory 
mediators due to the allergic reaction.6 Intranasal corticosteroids inhibit both early and late 
reactions and reduce IgE production and eosinophilia by inhibiting the secretion of cytokines 
including interleukin 4 (IL-4), IL-5, and IL-13.3,6  
5.2 
Investigational Product: Mechanism of Action 
Olopatadine is a histamine H1 -receptor antagonist. Intranasal antihistamines have the potential 
to provide quick symptomatic relief but do not provide substantial benefits for the late-phase 
reaction of the allergic response that leads to nasal congestion. The antihistaminic activity of 
olopatadine has been documented in isolated tissues, animal models, and humans.9 It has been 
suggested that olopatadine is clinically superior to other anti-allergy molecules because of its 
strong antihistamine activity and unique ocular mast cell-stabilizing properties.3,9 
Glenmark  
CONFIDENTIAL 
Page 19 of 91 

GSP 301-303 
GPL/CT/2014/018/III  
Version 2.0 
 
Date 31-Aug-2016 
Mometasone is a corticosteroid that demonstrates potent anti-inflammatory properties. Although 
intranasal corticosteroids act on both early-phase and late-phase reactions, they have a slow onset 
of action and can take hours to several days to reach their maximum benefit with some patients 
failing to achieve full relief of symptoms. The precise mechanism of corticosteroid action on AR 
is not known. Corticosteroids have been shown to have a wide range of effects on multiple cell 
types (e.g., mast cells, eosinophils, neutrophils, macrophages, and lymphocytes) and mediators 
(e.g., histamine, eicosanoids, leukotrienes, and cytokines) involved in inflammation.10 
Mometasone furoate has a high affinity for the glucocorticoid receptor and a highly lipophilic 
nature; these characteristics contribute to its minimal systemic absorption and prolonged nasal 
contact time. 
5.3 
Preclinical Experience 
The toxicity of both olopatadine hydrochloride and mometasone fuorate has been extensively 
assessed in multiple species by various routes of administration including intranasal 
administration. The Sponsor has conducted a 13-week intranasal toxicity study in rats in order to 
assess the potential toxicity of GSP 301 nasal spray (GSP 301 NS) and t
 
 GSP 301 NS 
(6650 μg/mL olopatadine hydrochloride and 250 μg/mL mometasone furoate [same as the 
formulation planned for the Phase 3 clinical studies]) was administered to rats by the nasal route 
up to 4 times daily. The high dose represented overages of 2.3-fold based on nasal surface area 
and approximately 50-fold on a mg/kg basis to the proposed dose to be studied in the Phase 3 
clinical studies. Equivalent concentrations of the individual components and a placebo were used 
as comparators. No nasal irritancy or systemic toxicity was noted in any groups in the study. 
Therefore, co-administration of the 2 components of the GSP 301 NS did not lead to any adverse 
effects. 
The acute toxicity of olopatadine hydrochloride and mometasone furoate is low. 
Repeat dose studies by the intranasal route have been conducted for both olopatadine 
hydrochloride and mometasone furoate in rats for up to 6 months and in dogs for up to 
12 months. Both compounds showed no nasal irritancy at concentrations equivalent to, or 
slightly greater than, those proposed in the fixed dose combination (FDC) GSP 301 NS.11,12,13  
Toxicity studies with olopatadine indicated no significant toxicity in repeated dose studies and 
other than typical corticosteroid effects, no target organ toxicity was determined with 
mometasone. Carcinogenicity studies have not been conducted by the intranasal route but neither 
compound was carcinogenic in rats or mice by the oral route. There was no evidence of 
genotoxicity with either compound. Therefore, the FDC is not considered to pose a genetic 
hazard or increase the risk of cancer to patients. 
No effect on fertility was observed with mometasone furoate but olopatadine hydrochloride 
administered orally to rats at 400 mg/kg/day resulted in a decrease in fertility index and reduced 
mean implantations. No effect on fertility was observed at 50 mg/kg/day (approximately 
100 times the maximum human dose of 4800 μg/day on a body surface area basis). 
Olopatadine hydrochloride was not teratogenic in rabbits and rats by the oral route; however, 
mometasone furoate has been shown to induce teratogenicity in multiple species by multiple 
routes with typical malformations and skeletal variations (reduced ossification) considered to be 
glucocorticoid class effects. It is known that the sensitivity of rodents to teratogenic effects of 
Glenmark  
CONFIDENTIAL 
Page 20 of 91 

GSP 301-303 
GPL/CT/2014/018/III  
Version 2.0 
 
Date 31-Aug-2016 
corticosteroids is greater than for humans; however, mometasone furoate should be used during 
pregnancy only if the potential benefits justify the potential risk to the fetus. Difficult and 
prolonged parturition observed in Segment I and Segment III reproduction studies may be related 
to the progestational effect of mometasone furoate. Both molecules are defined as Pregnancy 
Category C. 
Olopatadine hydrochloride tested negative for antigenic potential in mice and guinea pigs and 
was non-sensitizing in the guinea pig maximization test.  
5.4 
Clinical Experience 
A proof-of-concept study was conducted to evaluate FDC GSP 301 NS in the treatment of 
seasonal allergic rhinitis (SAR). This was a double-blind, double-dummy, randomized, 
parallel-group, comparative environmental chamber study to evaluate efficacy, safety, and 
tolerability of 2 Sponsor-formulated FDC products of olopatadine hydrochloride and 
mometasone furoate nasal spray (NS) (referred to as Molo 1 and Molo 2 in that study) compared 
with an approved FDC of azelastine hydrochloride and fluticasone propionate NS (Dymista 
NS), an approved olopatadine hydrochloride NS (Patanase® NS), and Sponsor-formulated 
placebo in subjects with SAR. The study population consisted of 180 subjects who were allergic 
to ragweed allergen and had SAR for the 2 years prior to study entry. Subjects were treated with 
study medication for 2 weeks. Both Sponsor-formulated FDC products were superior to placebo 
and Patanase® NS for the change from baseline in mean instantaneous Total Nasal Symptom 
Score (iTNSS). However, the Sponsor-formulated FDC products were not statistically superior 
to Dymista NS but showed numerical improvement. 
In addition, two Phase 1 pharmacokinetic (PK) studies and a large Phase 2 study were 
completed. The Phase 1 studies were open-label, 3-period, 3-treatment, crossover, randomized 
studies with 30 healthy volunteers in each study. The results of the two Phase 1 studies 
demonstrated that the olopatadine systemic exposure of the FDC GSP 301 NS is similar to the 
olopatadine exposure of the marketed monotherapy Patanase® NS and suggested that the 
mometasone furoate systemic exposure of the FDC GSP 301 NS is generally comparable to the 
mometasone furoate exposure of the marketed monotherapy Nasonex® NS, except for a higher 
maximum plasma concentration (Cmax) for the FDC GSP 301 NS 
compared with Nasonex® NS treatment. It is unlikely that the difference in mometasone furoate 
systemic exposure seen in this study (especially in terms of increased Cmax) is clinically 
significant concerning systemic safety. It should be noted that both of these Phase 1 studies used 
single doses of the GSP 301 NS formulation referred to as GSP 301-1 NS (
formulation of the FDC 
 
 in the Phase 2 Study GSP 301-201. 
Glenmark  
CONFIDENTIAL 
Page 21 of 91 

*63
*3/&7,,,
9HUVLRQ

'DWH$XJ 
7KH3KDVHGRXEOHEOLQGUDQGRPL]HGPXOWLFHQWHUVWXG\*63LQFOXGHG
VXEMHFWVZLWKDKLVWRU\RI6$5IRUDWOHDVW\HDUVDQGZKRZHUHDOOHUJLFWRPRXQWDLQFHGDU
DOOHUJHQ6XEMHFWVZHUHUDQGRPL]HGWRRIWUHDWPHQWJURXSV
x )'&RIRORSDWDGLQHK\GURFKORULGHDQGPRPHWDVRQHIXURDWH16*6316>RORSDWDGLQH
K\GURFKORULGHJDQGPRPHWDVRQHIXURDWHJ@DW
LQWKH
PRUQLQJ$0
x )'&RIRORSDWDGLQHK\GURFKORULGHDQGPRPHWDVRQHIXURDWH16*6316>RORSDWDGLQH
K\GURFKORULGHJDQGPRPHWDVRQHIXURDWHJ@DW
%,'LQWKHPRUQLQJDQGHYHQLQJ30
x *OHQPDUNRORSDWDGLQHK\GURFKORULGHJ16
x *OHQPDUNRORSDWDGLQHK\GURFKORULGHJ16
x *OHQPDUNPRPHWDVRQHIXURDWHJ16
x *OHQPDUNPRPHWDVRQHIXURDWHJ16
x *63SODFHER16*63YHKLFOH
7KHSULPDU\HQGSRLQWRIWKHVWXG\ZDVPHDQFKDQJHLQWKHUHIOHFWLYH7RWDO1DVDO6\PSWRP
6FRUHU7166IURPEDVHOLQHWRHQGRIWUHDWPHQWEHWZHHQWUHDWPHQWJURXSV7KHUHVXOWVRIWKH
VWXG\VXJJHVWHGWKDW*6316LVVWDWLVWLFDOO\DQGFOLQLFDOO\VXSHULRUWRSODFHEROHDVW
VTXDUHVPHDQ>/60@WUHDWPHQWGLIIHUHQFH>FRQILGHQFHLQWHUYDO^&,`@ >
@SIRUWKH)XOO$QDO\VLV6HW)$67KHPHDQFKDQJHIURPEDVHOLQHLQWKH
U7166VFRUHZDVFOLQLFDOO\DQGVWDWLVWLFDOO\VXSHULRUWRERWKPRPHWDVRQHIXURDWH16%,'/60
WUHDWPHQWGLIIHUHQFH
DQGRORSDWDGLQH
K\GURFKORULGH16%,'/60WUHDWPHQWGLIIHUHQFH
@ 
S $GGLWLRQDOO\*6316
ZDVDOVRVWDWLVWLFDOO\DQGFOLQLFDOO\VXSHULRUWR
SODFHER/60WUHDWPHQWGLIIHUHQFH>&,@ >@SIRU
PHDQFKDQJHIURPEDVHOLQHLQWKHL7166VFRUHNH\VHFRQGDU\HQGSRLQWIRUWKH)$6+RZHYHU
PHDQFKDQJHIURPEDVHOLQHLQWKHL7166VFRUHZDVFOLQLFDOO\DQGVWDWLVWLFDOO\VXSHULRUWR
PRPHWDVRQHIXURDWH16
/60WUHDWPHQWGLIIHUHQFH>&,@ >@
S EXWQRWRORSDWDGLQHK\GURFKORULGH16
/60WUHDWPHQWGLIIHUHQFH
>&,@ >@S 
%DVHGRQWKHGDWDIURPWKH3KDVHDQGVWXGLHV*6316
RI
RORSDWDGLQHK\GURFKORULGHJDQGPRPHWDVRQHIXURDWHJDQGUHIHUUHGWRDV*6316
KHUHDIWHULQWKLVSURWRFROZDVIRXQGWREHRSWLPDOO\VDIHDQGHIIHFWLYHIRUWKHWUHDWPHQWRI6$5
LQDGXOWDQGDGROHVFHQWVDQGZLOOEHIXUWKHUHYDOXDWHGLQWKH3KDVHVWXGLHV$GGLWLRQDOGHWDLOVRI
WKHSURGXFWDUHSURYLGHGLQWKH,QYHVWLJDWRU¶V%URFKXUH,%

6WXG\5DWLRQDOH
,WKDVEHHQVXJJHVWHGWKDWRORSDWDGLQHK\GURFKORULGHLVFOLQLFDOO\VXSHULRUWRRWKHUDQWLDOOHUJ\
PROHFXOHVEHFDXVHRILWVVWURQJDQWLKLVWDPLQHDFWLYLW\DQGXQLTXHRFXODUPDVWFHOOVWDELOL]LQJ
*OHQPDUN
&21),'(17,$/
3DJHRI
Z

GSP 301-303 
GPL/CT/2014/018/III  
Version 2.0 
 
Date 31-Aug-2016 
properties.3 The efficacy and safety of mometasone furoate NS, 50 µg (Nasonex® NS 200 µg 
total daily dose, QD) in the prophylaxis and treatment of nasal symptoms of SAR, nasal 
congestion associated with SAR and the treatment of perennial allergic rhinitis (PAR) have been 
evaluated in 18 controlled trials, and 1 uncontrolled clinical trial, in approximately 3000 adults 
(aged 17 to 85 years) and adolescents (aged 12 to 16 years).10 
f
 
 Olopatadine hydrochloride and mometasone furoate, the 
monocomponents in GSP 301 NS, are approved in the US. The safety, including long-term 
safety, of these drugs is well established.  
As the proposed GSP 301 NS is to be used to treat chronic rhinitis, it is important to evaluate the 
safety of the product during long-term use. The US Food and Drug Administration (FDA) 
guidance on the development of drug product for AR recommends that a new product should be 
evaluated in a long-term (52 weeks) safety study. Therefore, the optimal dose and regimen 
determined based on the Phase 2 study, will be further tested in this protocol to evaluate the 
long-term safety and efficacy of GSP 301 NS compared with placebo NS formulations.  
GSP 301 NS is an aqueous nasal spray containing olopatadine hydrochloride and mometasone 
furoate monohydrate as the active ingredients in an aqueous solution with an approximate pH of 
 Although, matching pH of the active product 
 is essential to maintain blinding for 
efficacy purposes; the low pH in the placebo treatment may impact the interpretation of the 
safety data because the frequencies of commonly occurring adverse events (AEs) in the GSP301 
NS group may be underestimated when compared with the low pH placebo treatment group. To 
address this issue, an additional placebo NS with a higher pH of approximately 
 is being 
evaluated in this study as recommended by the US FDA. Thus, the primary objective of this 
study is to compare the long-term safety and tolerability of GSP 301 NS with two GSP 301 
placebo NS formulations over 52 weeks of treatment in subjects (aged ≥12 years) with PAR. 
Additionally, the long-term efficacy of GSP 301 NS will also be evaluated.  
5.6 
Benefit-Risk Assessment 
Olopatadine hydrochloride NS (Patanase® NS) has been approved for the relief of the symptoms 
of SAR in adults and children ≥6 years of age since 2008 in the US. It has a fast onset of action 
and is effective within 30 minutes of administration. The most common (>1% of patients) 
adverse reactions included bitter taste, headache, epistaxis, pharyngolaryngeal pain, post-nasal 
drip, cough, and urinary tract infection.9 
Mometasone furoate NS (Nasonex® NS) is also well tolerated, effective, and safe in the 
treatment of seasonal and perennial AR. Nasonex® NS was approved in the US in 1997 for the 
treatment of the nasal symptoms associated with AR and the nasal congestion associated with 
SAR, respectively. The most common adverse reactions (≥5% of patients) included headache, 
viral infection, pharyngitis, epistaxis, cough, upper respiratory tract infection, sinusitis, 
dysmenorrhea, and musculoskeletal pain.10   
The currently approved dose of olopatadine hydrochloride (Patanase® NS, 665 μg, equivalent to 
600 μg olopatadine as base) monotherapy in adults and adolescents ≥12 years old with SAR is 
2 sprays in each nostril BID. The currently approved dose of mometasone furoate (Nasonex® NS, 
50 μg) monotherapy in adults and adolescents ≥12 years old with AR is 2 sprays in each nostril 
QD. Thus, the approved total daily doses for the monotherapies are 5320 μg olopatadine 
Glenmark  
CONFIDENTIAL 
Page 23 of 91 

*63
*3/&7,,,
9HUVLRQ
'DWH$XJ 
K\GURFKORULGHDQGȝJPRPHWDVRQH IX RD H: KWKH SURSRVHG*6316UHJLPHQ
WKH
WRWDOGDLO\GRVHRIRORSDWDGLQHK\GURFKORULGHDQGPRPHWDVRQHIXURDWHZLOOEH

6HYHUDOFOLQLFDOVWXGLHVKDYHDOUHDG\VKRZQWKDWDFRPELQDWLRQRIDQLQWUDQDVDODQWLKLVWDPLQHDQG
DQLQWUDQDVDOFRUWLFRVWHURLGLVEHQHILFLDOZLWKUHVSHFWWRORFDODGPLQLVWUDWLRQDQGDQDGGLWLYH
HIIHFWRQHIILFDF\UHVXOWLQJLQVXSHULRUUHOLHIRI6$5V\PSWRPVFRPSDUHGZLWKPRQRWKHUDS\
$FOLQLFDOVWXG\GHPRQVWUDWHGWKDWDFRPELQDWLRQRID]HODVWLQHDQGIOXWLFDVRQH16'\PLVWD
16ZDVPRUHHIIHFWLYHWKDQHLWKHUDJHQWDORQHLQWKHWUHDWPHQWRI6$5,Q'\PLVWD16
PJD]HODVWLQHK\GURFKORULGHDQGPJIOXWLFDVRQHSURSLRQDWHZDVDSSURYHGLQWKH86
)URPDVDIHW\SHUVSHFWLYHVWXGLHVGRQHVRIDUZLWKWKH*6316)'&LQFOXGLQJWKH3KDVH
VWXG\GLGQRWUHSRUWDQ\PDMRU$(VRUVDIHW\FRQFHUQV
7KHUHIRUH
)'&RIRORSDWDGLQHK\GURFKORULGHDQGPRPHWDVRQHIXURDWH
*6316 Z
SURYHGHIILFDF\FRPSDUHGZLWKHDFKLQGLYLGXDOPRQRWKHUDS\DQGWKDW
WKHVDIHW\ZLOOEHVLPLODUWRWKHNQRZQVDIHW\SURILOHVRIHDFKPRQRWKHUDS\

678'<2%-(&7,9(6

3ULPDU\2EMHFWLYH
x
7RFRPSDUHWKHORQJWHUPVDIHW\DQGWROHUDELOLW\RI*6316ZLWK*63SODFHER16
IRUPXODWLRQVRYHUZHHNVRIVWXG\WUHDWPHQW

6HFRQGDU\2EMHFWLYH
x
7RHYDOXDWHWKHORQJWHUPHIILFDF\RI*6316FRPSDUHGZLWK*63SODFHER16
S+
LQVXEMHFWVZLWK3$5

([SORUDWRU\2EMHFWLYH
1RWDSSOLFDEOH
 678'<'(6,*1

6WXG\7\SH'HVLJQ
7KLVLVDPXOWLFHQWHUGRXEOHEOLQGUDQGRPL]HGSDUDOOHOJURXSZHHNVWXG\FRQGXFWHGLQ
VXEMHFWVZLWK3$57KHVXEMHFWVZLOOEHUDQGRPL]HGWRWKHIROORZLQJWUHDWPHQWJURXSVLQD
UDWLRRI
x
*63 1

RSD
QH
GURFK RULGHJPRPHWDVRQHIXURDWHDGPLQLVWHUHGDV
x
*63 SODFHER16S+
DGPLQLVWHUHGDV
*OHQPDUN
&21),'(17,$/
3DJHRI

S

\
S
\
\
ȝJ
S
S
J

GSP 301-303 
GPL/CT/2014/018/III  
Version 2.0 
 
Date 31-Aug-2016 
 
(Visit 12). 
No scheduled post-treatment follow-up visit is planned for this study. However, subjects will be 
followed up if there is any ongoing AE or for any other reason as per the Investigator’s and 
Sponsor’s discretion.  
A telephone follow-up will be carried out for this study for any reason as per the Investigator’s 
judgment. If needed, additional unscheduled visits may be conducted to ensure subject safety or 
to perform other study-related procedures at the discretion of the Investigator or the Sponsor. 
No extension phase is planned for this study. 
7.2 
Discussion of Study Design, Including Choice of Control Groups 
This will be a multi-center, double-blind, randomized, parallel-group study conducted in 
approximately 600 subjects with PAR. These subjects will be randomized to 1 of the 3 treatment 
arms in a ratio of 4:1:1. Randomization will be stratified by study site. 
The study is designed as a double-blind study to reduce treatment and randomization bias. The 
overall study design is consistent with other similar studies reported in the literature. 
Furthermore, the overall study design is also based on the FDA guidance document for Allergic 
Rhinitis: Clinical Development Programs for Drug Products by the US FDA.14 
This current study is planned to compare the long-term safety and efficacy of GSP 301 NS to 
2 different GSP 301 placebo NS formulations as agreed at an End-of-Phase 2 (EOP2) meeting 
with the FDA.
 
 All NS bottles for all treatment groups will be 
identical in appearance. Thus, other than the active components and/or pH of the placebo 
formulations (as appropriate), there are no other differences in the formulations or the bottles of 
the 3 treatments.  
8 STUDY ENDPOINTS 
8.1 
Primary Endpoints 
• Proportion of subjects with TEAEs. 
• Proportion of subjects with treatment-related TEAEs. 
• Incidence, type, and severity of the TEAEs after 30 weeks of study treatment. 
• Incidence, type, and severity of the TEAEs after 52 weeks of study treatment.  
• Clinical laboratory assessments (hematology, serum biochemistry, and urinalysis) at baseline, 
Week 30, and Week 52. 
• Vital signs, physical examinations (PE), and focused ears, nose, and throat (ENT) and eye 
examinations at baseline, Week 30, and Week 52. 
Glenmark  
CONFIDENTIAL 
Page 26 of 91 

GSP 301-303 
GPL/CT/2014/018/III  
Version 2.0 
 
Date 31-Aug-2016 
8.2 
Secondary Endpoints 
8.2.1 
Efficacy Endpoints 
• Change from baseline in the average AM subject-reported rTNSS over the first 6, 30, and 52 
weeks of treatment.  
• Change from baseline in the average AM subject-reported iTNSS over the first 6, 30, and 52 
weeks of treatment. 
• Change from baseline in the overall Rhinoconjunctivitis Quality of Life Questionnaire – 
Standardized Activities (RQLQ(S)) score at Weeks 6, 30, and 52 for the FAS. 
8.2.2 
Other Efficacy Endpoints  
Nasal Symptoms: 
• Change from baseline in the average AM subject-reported reflective individual nasal 
symptoms over the first 6, 30, and 52 weeks of treatment.  
• Change from baseline in the average AM subject-reported instantaneous individual nasal 
symptoms over the first 6, 30, and 52 weeks of treatment.  
• Change in the average AM subject-reported rTNSS and iTNSS from baseline to the end of 
each treatment week. 
• Change in the average AM subject-reported reflective individual nasal symptoms from 
baseline to the end of each treatment week.  
• Change in the average AM subject-reported instantaneous individual nasal symptoms from 
baseline to the end of each treatment week. 
• Physician assessed Nasal Symptom Score (PNSS), Rhinoconjunctivitis Quality of Life 
Questionnaire – Standardized Activities (RQLQ(S)), and Rhinitis Control Assessment Test 
(RCAT): 
• Change from baseline in PNSS and physician assessed individual nasal symptoms at 
Weeks 6, 30, and 52. 
• Change from baseline in individual domains of the RQLQ(S) at Weeks 6, 30, and 52 for the 
FAS. 
• Change from baseline in overall RQLQ(S) score and individual domains of the RQLQ(S) at 
Weeks 6, 30, and 52 for the RQLQ(S) Analysis Set. 
• Change from baseline in the RCAT at Weeks 6, 30, and 52. 
• Change from baseline in individual domains of the RCAT at Weeks 6, 30, and 52. 
8.3 
Exploratory Endpoint 
Not applicable. 
Glenmark  
CONFIDENTIAL 
Page 27 of 91 

GSP 301-303 
GPL/CT/2014/018/III  
Version 2.0 
 
Date 31-Aug-2016 
8.4 
Appropriateness of Measurements 
The planned safety analysis and the change in the rTNSS as an efficacy endpoint for the current 
study are as per the available safety data on the individual monotherapies and the other available 
FDC product on the US market (Dymista USPI),15 and the US FDA guidance on the 
development of AR medication.14 
9 SUBJECT SELECTION AND WITHDRAWAL CRITERIA 
Approximately 600 subjects (both male and female) will be randomized at multiple sites in the 
US. Subjects who do not meet all of the inclusion criteria or who meet any of the exclusion 
criteria will not be eligible to enter in the study. 
Subject eligibility should be reviewed and documented by an appropriately qualified member of 
the Investigator’s study team before each subject is included in the study. 
Any subject who fails screening on any single criterion where there is the potential for them to 
subsequently become eligible may be re-screened on 1 occasion, dependent upon consultation 
with the Sponsor’s study team and approval.  
9.1 
Inclusion Criteria 
Subjects must meet all of the following criteria to be enrolled in the study: 
1. Males and non-pregnant females aged ≥12 years.  
2. Signed informed consent/assent form (subject and/or parent/caregiver/legal guardian) that 
meets all criteria of the current US FDA/local regulations. 
3. Documented clinical history of PAR (for at least 2 years preceding the Screening Visit 
[Visit 1]) with exacerbations (clinical evidence of active symptoms) and exhibiting a 
documented positive skin prick test (wheal diameter at least 3 mm greater than negative 
diluent control wheal) to at least 1 allergen known to induce PAR. Documentation of a 
positive result within 12 months prior to the Screening Visit (Visit 1) is acceptable. 
Additionally, the subject is expected to be exposed to the PAR allergen that he/she tested 
positive for via the skin prick test for the entire duration of the study. 
4. General good health and free of any disease or concomitant treatment that could interfere 
with the interpretation of study results as determined by the Investigator. 
5. Subjects must be able to demonstrate the correct NS application technique at the Screening 
Visit (Visit 1). 
6. Subjects must be willing and able to comply with all aspects of the protocol. 
9.2 
Exclusion Criteria 
Subjects who meet any of the following criteria must not be enrolled in the study:    
1. Have a positive pregnancy test or established pregnancy, breast-feeding, or planning a 
pregnancy during the study. 
2. Female subjects of child-bearing potential (as judged by the Investigator) who do not agree to 
remain abstinent or use medically acceptable methods of contraception (e.g., implants, 
Glenmark  
CONFIDENTIAL 
Page 28 of 91 

GSP 301-303 
GPL/CT/2014/018/III  
Version 2.0 
 
Date 31-Aug-2016 
injectables, combined oral contraceptives, intrauterine devices [IUDs], double-barrier 
protection) during the study. Male participants who do not agree to use a condom with 
spermicide during intercourse (if not surgically sterilized) during the study. 
3. History of significant atopic dermatitis or rhinitis medicamentosa (within 60 days prior to the 
Screening Visit [Visit 1]). 
4. Treatment with any known potent CYP3A4 inducers (carbamazepine, dexamethasone, 
phenytoin, rifabutin, rifampin, pioglitazone, etc.) or potent inhibitors (azole antifungals, 
macrolide antibiotics, etc.) within 30 days prior to or during the study. 
5. Non-vaccinated exposure to or active infection with chickenpox or measles within 21 days 
preceding the Screening Visit (Visit 1). 
6. Known hypersensitivity to any corticosteroids or antihistamines or to the study medication or 
its excipients. 
7. History of anaphylaxis and/or other severe local reaction(s) to skin testing. 
8. History of alcohol or drug dependence within 2 years preceding the Screening Visit (Visit 1). 
9. History of a positive test for human immunodeficiency virus (HIV), Hepatitis B, or 
Hepatitis C infection. 
10. Evidence of acute or significant chronic sinusitis or chronic purulent postnasal drip. 
11. Any of the following conditions (including but not limited to the following) that are judged 
by the Investigator to be clinically significant and/or to affect the subject’s ability to 
participate in this study: 
• Impaired hepatic function including alcohol-related liver disease or cirrhosis 
• Any systemic infection 
• Hematological, hepatic, renal, endocrine disorder (except for postmenopausal symptoms 
or hypothyroidism) 
• Gastrointestinal disease 
• Malignancy (excluding basal cell carcinoma) 
• Current neuropsychological condition with or without drug therapy 
• Cardiovascular disease (e.g., uncontrolled hypertension) 
• Respiratory disease other than mild asthma 
12. Any major surgery (as assessed by the Investigator) within 4 weeks preceding the Screening 
Visit (Visit 1). 
13. Requirement for the chronic use of tricyclic anti-depressants. 
14. Dependence (in the opinion of the Investigator) on nasal, oral, or ocular decongestants, nasal 
topical antihistamines, or nasal steroids. 
15. Active pulmonary disorder or infection (including but not limited to bronchitis, pneumonia, 
or influenza), or upper respiratory tract or sinus infection within the 14 days prior to the 
Screening Visit (Visit 1) or the development of respiratory infections during the run-in 
Glenmark  
CONFIDENTIAL 
Page 29 of 91 

GSP 301-303 
GPL/CT/2014/018/III  
Version 2.0 
 
Date 31-Aug-2016 
period. Subjects with mild asthma are allowable on the condition that treatment is limited to 
inhaled short-acting beta-agonists only (up to 8 puffs per day). 
16. Use of antibiotic therapy for acute conditions within 14 days prior to the Screening Visit 
(Visit 1). Low doses of antibiotics taken for prophylaxis are allowed if the therapy was 
started prior to the Screening Visit (Visit 1) and is expected to continue at the same stable 
dose throughout the clinical study duration. 
17. Posterior subcapsular cataracts or glaucoma, or any other ocular disturbances, or other listed 
related conditions including: 
• History of increased intraocular pressure 
• History of retinal detachment or surgery 
• History of incisional eye surgery (other than cataract extraction or laser-assisted in situ 
keratomileusis [LASIK]) 
• History of penetrating ocular trauma, severe blunt ocular trauma 
• Evidence of uveitis, iritis, or other inflammatory eye disease during screening 
• Presence of ocular herpes simplex 
18. Known history of hypothalamic-pituitary-adrenal axis impairment.  
19. Existence of any significant surgical or medical condition, or clinically significant physical 
finding (e.g. significant nasal polyps or other clinically significant respiratory tract 
malformations/nasal structural abnormalities, significant nasal trauma [such as nasal 
piercing] or significant nasal septal deviation) which, in the opinion of the Investigator or 
Sponsor’s medical monitor, significantly interferes with the absorption, distribution, 
metabolism or excretion of the study medication or significantly interferes with nasal air flow 
or interferes with the subject’s ability to complete or reliably complete the AR Assessment 
Diary. 
20. Participation in any investigational non-biological drug clinical study in the 30 days or 
investigational biological drug in the 120 days preceding the Screening Visit (Visit 1) or 
planned participation in another investigational clinical study at any time during the current 
study. 
21. Initiation of immunotherapy injections or immunosuppressive/immune-modulator 
medications (except topical pimecrolimus cream or tacrolimus ointment if initiated at least 
30 days prior to screening and maintained on stable dose) within 60 days preceding the 
Screening Visit (Visit 1). A 180-day washout period is required following the last dose of 
sublingual immunotherapy (investigational or other) prior to the Screening Visit (Visit 1).   
22. Use of topical corticosteroids in concentrations in excess of 1% hydrocortisone or equivalent 
within 30 days prior to the Screening Visit (Visit 1); use of a topical hydrocortisone or 
equivalent in any concentration covering greater than 20% of the body surface; or the 
presence of an underlying condition (as judged by the Investigator) that can reasonably be 
expected to require treatment with such preparations during the clinical study duration. 
23. Study participation by clinical investigational site employees and/or their immediate 
relatives. 
Glenmark  
CONFIDENTIAL 
Page 30 of 91 

GSP 301-303 
GPL/CT/2014/018/III  
Version 2.0 
 
Date 31-Aug-2016 
24. Study participation by more than 1 subject from the same household at the same time. 
However, after completion/discontinuation by 1 subject in the household, another subject 
from the same household may be screened. 
25. Known to have failed to show symptom improvement with any approved/marketed 
monotherapy component of GSP 301 NS (i.e., Nasonex® NS or Patanase® NS or both) as 
judged by the Investigator. 
26. Previous participation in a GSP 301 NS study as a randomized subject. 
9.3 
Randomization Criteria 
1. Continued general good health meeting the Screening inclusion criteria. 
2. Has not experienced an AE that would result in not meeting the Screening inclusion criteria. 
3. Minimum AM subject-reported rTNSS of an average of 5 (out of a possible 12) during the 
last 4 days of the run-in period (last 4 consecutive AM assessments from the Day -3 AM 
assessment to the AM assessment on the day of randomization). 
4. Has an AM subject-reported reflective nasal congestion score ≥2 during the last 4 days of the 
run-in period (last 4 consecutive AM assessments from the Day -3 AM assessment to the AM 
assessment on the day of randomization).  
5. Adequate AR Assessment Diary compliance – inadequate compliance is defined as missing 1 
or more of the entries on 2 or more assessment sessions (AM) during the last 4 days of the 
run-in period (during the last 4 consecutive AM assessments from the Day -3 AM assessment 
to the AM assessment on the day of randomization). 
6. Adequate study medication compliance – each subject must have taken his/her single-blind 
medication for at least 80% of the entire run-in period as reported in the AR Assessment 
Diary. 
7. Has not suffered from the common cold, upper respiratory infections, otitis media, lower 
respiratory infections, or acute sinusitis within the 14 days prior to the Randomization Visit 
(Visit 2). 
8. Has not used any of the prohibited concomitant medications during the run-in period. 
9.4 
Subject Discontinuation/Withdrawal Criteria 
A subject may voluntarily discontinue study participation at any time after giving informed 
consent and before the completion of the last visit of the study.  Subjects may also be withdrawn 
from study drug treatment at the discretion of the investigator or sponsor for safety, 
noncompliance, or administrative reasons. The Investigator may also discontinue the subject’s 
study participation at any time at his/her discretion and for any reason.  
The reasons for subject withdrawal will be recorded and may include, but are not limited to: 
1. Withdrawal of consent by the subject to continue in the study.   
2. Development of a serious or intolerable AE that necessitates discontinuation at the discretion 
of the Investigator (AE section of the CRF/eCRF must be completed; includes serious 
adverse event [SAE], death). 
Glenmark  
CONFIDENTIAL 
Page 31 of 91 

GSP 301-303 
GPL/CT/2014/018/III  
Version 2.0 
 
Date 31-Aug-2016 
3. At the discretion of the Investigator, when he/she believes continued participation is not in 
the best interest of the subject. 
4. At the discretion of the Investigator, when the subject does not adhere to the study 
procedures. 
5. A protocol deviation that, in the opinion of the Sponsor and Investigator, warrants 
discontinuation from the study. 
In the case of premature discontinuation, the reason must be documented. The Investigator (or 
designee) must document the reason for withdrawal in the Study Conclusion section of the 
CRF/eCRF.  
All follow-up assessments should be conducted as outlined for the Final Visit/Discontinuation 
Visit (Visit 12) (Appendix 1). Every effort should be made to contact the subject for a follow-up 
if the subject has not returned to the clinic for scheduled visits (lost-to-follow up subject) to 
ensure the safety of the subject. If the subject withdraws consent for the study, no further 
evaluation will be performed and no additional data or medical records will be collected. The 
sponsor may retain and continue to use any data collected before withdrawal of consent. 
A subject who discontinues study treatment early but does not withdraw consent, should return 
for end of study assessments, as noted in Section 11.4.   
The investigator will: 
• inquire about the reason for withdrawal,  
• request that the subject return all unused investigational product(s), and  
• request that the subject return for the Final Visit/Discontinuation Visit (Visit 12).   
If the subject refuses to attend the clinic, efforts will be made and documented, to perform the 
end of study assessments; collection of visit data during a telephone call is permitted. 
The investigator must request follow up with the subject regarding any unresolved AEs/SAEs. 
As a minimum, at the end of the study, the Investigator should consult public records to 
determine the subject’s circumstances, e.g. vital status, incarceration or relocation. 
Discontinued subjects will not be replaced.  
9.5 
Sponsor Discontinuation Criteria  
Premature termination of this study may occur because of a regulatory authority decision, change 
in opinion of the Institutional Review Board (IRB)/Independent Ethics Committee (IEC), drug 
safety problems, or at the discretion of the Sponsor for any other reason. In addition, the Sponsor 
retains the right to discontinue development of GSP 301 NS at any time. 
If this study is prematurely terminated or discontinued, the Sponsor will promptly notify the 
Investigator. After notification, the Investigator must contact all participating subjects and the 
hospital pharmacy (if applicable) within a time period set by the Sponsor. As directed by the 
Sponsor, all study materials must be collected and all CRFs/eCRFs completed to the greatest 
extent possible. 
Glenmark  
CONFIDENTIAL 
Page 32 of 91 

GSP 301-303 
GPL/CT/2014/018/III  
Version 2.0 
 
Date 31-Aug-2016 
9.6 
Prior and Concomitant Medications 
Exclusion of Medication Prior to the Screening Visit (Visit 1): 
1. 
Vasoconstrictors (e.g, epinephrine, sumatriptan) 
3 days 
2. 
Major tranquilizers (e.g., antipsychotics such as chlorpromazine, haloperidol, 
risperadol, clonazepam) 
3 days 
3. 
Short-acting antihistamines (oral, ocular, or intranasal antihistaminic– e.g., 
azelastine)  
7 days 
4. 
Over-the-counter (OTC) cough and cold preparations or sleep aids containing 
antihistamines  
7 days 
5. 
Topical/oral/nasal decongestants (e.g., oxymetazoline, pseudoephedrine, 
tetrahydrozoline)  
7 days 
6. 
OTC food supplement/diet to reduce leukotrienes (Airozin) 
7 days 
7. 
Leukotriene antagonists or arachidonate 5-lipoxygenase inhibitors 
7 days 
8. 
Inhaled/oral/intranasal anticholinergics 
7 days 
9. 
Long-acting antihistamines (e.g., cetirizine, fexofenadine)  
10 days 
10. Cromolyn (all forms), nedocromil, or lodoxamide (intranasal, ocular, or oral)   14 days 
11. Systemic antibiotics (see excluded concomitant medications) 
14 days 
12. Ocular mast cell stabilizers 
14 days 
13. Monoamine oxidase inhibitors 
14 days 
14. Tricyclic antidepressants 
14 days 
15. All intranasal/topical/ocular corticosteroids (except study medication) 
30 days 
16. Inhaled corticosteroids 
30 days 
17. Any other investigational non-biological drug 
30 days 
18. Treatment with any known potent CYP3A4 inducers (carbamazepine, 
dexamethasone, phenytoin, rifabutin, rifampin, pioglitazone, etc.) 
30 days 
19. Treatment with any known potent CYP3A4 inhibitors (azole antifungals, 
macrolide antibiotics, etc.) 
30 days 
Glenmark  
CONFIDENTIAL 
Page 33 of 91 

GSP 301-303 
GPL/CT/2014/018/III  
Version 2.0 
 
Date 31-Aug-2016 
20. Systemic corticosteroids (intermittent or chronic including intra-articular) 
60 days 
21. Immunotherapy injections and immunosuppressive/immune-modulator 
medications (except topical pimecrolimus cream or tacrolimus ointment if 
initiated at least 30 days prior to screening and maintained on stable dose) 
60 days 
22. IgE antagonist or any other anti-IgE therapy 
120 days 
23. Any other investigational biological drug 
120 days 
24. Anti-IL-5 therapy (e.g., reslizumab, mepolizumab, etc.) 
120 days 
25. Sublingual immunotherapy (investigational or other) 
180 days 
These above medications are also prohibited throughout the entire study except for rescue 
medications (see Rescue Medications text). In addition, the following medications are 
prohibited throughout the entire study: 
1. All intranasal therapies (including saline) other than study medication 
2. Topical corticosteroids (except for the treatment of small, localized lesions) 
3. Radiation therapy 
4. Initiation of immunotherapy 
5. Any investigational drug being used in another clinical study 
6. Herbal medications/supplements to treat AR, or any other alternative therapies to treat AR 
7. St. John’s Wort (Hypericum perforatum) 
8. Guaifenesin-containing products (e.g., Mucinex) 
Exclusion of Concomitant Medications: 
1. No asthma preventive medication will be permitted during the study except for inhaled 
short-acting beta-agonists for mild asthma (up to 8 puffs per day). 
2. Subjects can receive topical immunotherapy (e.g., pimecrolimus cream or tacrolimus 
ointment), provided initiation of topical immunotherapy was at least 30 days prior to the 
Screening Visit (Visit 1) and the subject uses a stable maintenance dose (30 days or more) 
prior to the Screening Visit (Visit 1) as well as during the study.  
3. Potent CYP3A4 inhibitors (such as ketoconazole, itraconazole, erythromycin) and potent 
CYP3A4 inducers (such as carbamazepine, dexamethasone, phenytoin, rifabutin, rifampin, 
pioglitazone) are prohibited 30 days prior to the Screening Visit (Visit 1) as well as during 
the study. 
4. Use of antibiotic therapy for acute conditions within 14 days prior to the Screening Visit 
(Visit 1). Low doses of antibiotics taken for prophylaxis are allowed if the therapy was 
started prior to the Screening Visit (Visit 1) and is expected to continue at the same stable 
dose throughout the clinical study duration. 
Glenmark  
CONFIDENTIAL 
Page 34 of 91 

GSP 301-303 
GPL/CT/2014/018/III  
Version 2.0 
 
Date 31-Aug-2016 
Rescue Medications: 
The following rescue medication, non-nasal formulations only, is allowed in the study ONLY 
after Treatment Visit 4 (Week 6): 
1. Loratadine (10 mg/day) 
The use of rescue medications will be available only after the first 6 weeks of treatment (after 
Treatment Visit 4). No rescue medication will be provided or allowed during the placebo run-in 
period or prior to Day 43 of the treatment period. Usage of rescue medication must be recorded 
in the AR Assessment Diary that will be provided to the subjects. Subjects should be instructed 
that rescue medication use should be minimal and used only as needed when the subject’s 
symptoms are intolerable. Additional rescue medication should be prescribed only if the 
provided rescue medication (loratadine 10 mg/day) is not effective in relieving the symptoms as 
judged by the Investigator (e.g.topical/oral decongestants [e.g., oxymetazoline, pseudoephedrine, 
tetrahydrozoline], short-acting ocular antihistamines, long-acting antihistamines [e.g., 
desloratadine, cetirizine, fexofenadine], OTC cough and cold preparations or sleep aids 
containing antihistamines). Once the symptoms are deemed to be under control, rescue 
medication usage should be minimized or discontinued. Rescue medications should be used as 
prescribed by the Investigator/designee at approved dosages as applicable per the prescribing 
information of the medication. 
The use of all medication and non-medication therapies must be recorded on the concomitant 
medication pages of the subject’s CRF/eCRF. 
Permitted Medications: 
With the exception of medications listed as excluded, subjects will be allowed to use other 
chronic medications at stable doses and other medications at the discretion of the Investigator (in 
consultation with the Sponsor) provided that they do not interfere with the safety and efficacy 
variables of the study. 
9.7 
Lifestyle and/or Dietary Restrictions 
Not applicable. 
10 TREATMENT OF SUBJECTS 
10.1 
Treatments Administered 
Name of Investigational Product: FDC of olopatadine hydrochloride 665 µg and mometasone 
furoate 25 µg NS (GSP 301 NS) 
License Name: GSP 301-2 NS 
Dosage Form: NS 
Dosage: 
Dosage Frequency:
Mode of Administration: Intranasal 
Glenmark  
CONFIDENTIAL 
Page 35 of 91 

GSP 301-303 
GPL/CT/2014/018/III  
Version 2.0 
 
Date 31-Aug-2016 
Reference Product 1: GSP 301 Placebo NS 
License Name: GSP 301 Placebo NS 
Dosage Form: NS 
Dosage: 
Dosage Frequency: 
 
Mode of Administration: Intrana
Reference Product 2: GSP 301 Placebo NS pH 
License Name: GSP 301 Placebo NS pH 
Dosage Form: NS
Dosage: 
Dosage Frequency:
  
Mode of Administration: Intranasa
10.1.1 
Administration 
Each nasal spray bottle contains
 At the Screening Visit (Visit 1), site personnel will 
adequately train the subjects on the proper use of the NS bottle (Appendix 2). At each 
subsequent visit, site personnel will review instructions on the proper use of the NS bottle with 
the subject and prime the NS bottle as needed. The priming process must be completed in such a 
way as to avoid any possible inhalation and contamination by the subject.  
Each subject will be provided with single-blind, placebo, run-in medication (GSP 301 placebo 
NS pH
 for use until the Randomization Visit (Visit 2). Subjects will self-administer the first 
dose of the single-blind GSP 301 placebo NS pH 
 in the presence of the Investigator or 
designee during the Screening Visit (Visit 1). Subjects should be instructed NOT to administer 
the single-blind study medication on the day of the Randomization Visit (Visit 2). 
At the Randomization Visit (Visit 2), each subject will be provided with double-blind study 
medication according to the randomization scheme. The site personnel will review instructions 
on the proper use of the NS bottle with the subject and prime the NS bottle as needed. The 
priming process must be completed in such a way as to avoid any possible inhalation and 
contamination by the subject. The first dose of double-blind study medication (AM dose on 
Day 1) will be self-administered in the clinic in the presence of the Investigator or designee 
during the Randomization Visit (Visit 2). All subsequent doses will be administered at home. 
The last scheduled dose will be the
on the day before the Final Visit/Discontinuation 
Visit (Visit 12). Study medication shou d not be taken (either at home or at the clinic) on the 
morning of the Final Visit/Discontinuation Visit (Visit 12). 
Detailed instructions for the proper use of the treatment NS devices are provided in Appendix 2.  
10.1.2 
Treatment Adherence/Compliance 
All study medication will be self-administered in the clinical facility as well at home in 
accordance with the protocol-specified subject study medication instructions. Subject 
adherence/compliance to treatment will be monitored by reviewing the AR Assessment Diary 
entries as outlined in the Schedule of Procedures and Assessments (Appendix 1). Subjects will 
be counseled regarding proper treatment adherence/compliance and re-trained in the proper use 
of the study medication nasal spray bottle at the specified visits as well as reviewing the subject 
study medication instructions. 
Glenmark  
CONFIDENTIAL 
Page 36 of 91 

GSP 301-303 
GPL/CT/2014/018/III  
Version 2.0 
 
Date 31-Aug-2016 
10.1.3 
Treatment of Investigational Product Overdose 
Thus far, there are no data available on the effects of acute or chronic overdose with GSP 301 
NS based on the completed clinical studies. Because of the proven safety and efficacy of the 
individual monotherapy components of GSP 301 NS, overdose is unlikely to require any therapy. 
There is no specific antidote to be used in the event of overdose. The Investigator should observe 
the subject and use his/her clinical judgment in treating overdose as indicated by the subject’s 
clinical status. 
Overdose information for each individual component of GSP 301 NS (approved monotherapies) 
is provided in the prescribing information and outlined here.9,10 
Olopatadine hydrochloride: There have been no reported overdoses with olopatadine 
hydrochloride NS (Patanase® NS). Symptoms of antihistamine overdose may include drowsiness. 
There is no known specific antidote to olopatadine hydrochloride NS. Should overdose occur, 
symptomatic or supportive treatment is recommended, taking into account any concomitantly 
ingested medications. 
Mometasone furoate: No data are available on the effects of acute or chronic overdose with 
mometasone furoate monohydrate NS (Nasonex® NS). Overdose is unlikely to require any 
therapy because of the negligible (<0.1%) systemic bioavailability of mometasone furoate and 
the absence of acute drug-related systemic findings in clinical studies; however, observation 
followed by re-initiation of the appropriate prescribed dosage is recommended. 
10.2 
Identity of Investigational Products  
10.2.1 
Chemical Name and Structural Formulas 
 
 
Generic name: 
Olopatadine hydrochloride 
Chemical name: 
(Z)-11-[3-(dimethylamino)propylidene]-6,11-
dihydrodibenz[b,e]oxepin-2-acetic acid hydrochloride 
Structural formula: 
 
Glenmark  
CONFIDENTIAL 
Page 37 of 91 

GSP 301-303 
GPL/CT/2014/018/III  
Version 2.0 
 
Date 31-Aug-2016 
 
Generic name: 
Mometasone furoate 
Chemical name: 
9,21-Dichloro-11ß,17-dihydroxy-16α-methylpregna-1,4-diene-
3,20-dione17-(2 furoate) monohydrate 
Structural formula: 
 
10.2.2 
Placebo 
GSP 301 placebo NS formulations will be prepared using the same vehicle as the active 
products. The GSP 301 placebo NS bottle will be identical to that of active treatments. The 
GSP 301 placebo NS will be packaged in primary and secondary packaging similar to that of the 
active treatments to maintain study medication blinding. 
Two GSP 301 placebo NS formulations will be used in this study. GSP 301 placebo NS pH 
 is 
a placebo formulation matching the pH of the active product (pH 
. An additional GSP 301 
placebo NS pH 
 with a higher pH of approximately 
 is being evaluated in this study as 
recommended by the FDA. Other than the differences in pH and active ingredients, both placebo 
formulations used in the study are formulated in the same vehicle as GSP 301 NS and all NS 
bottles used for all treatment groups will be identical in appearance. 
10.2.3 
Packaging and Labeling of Investigational Products  
Each of the investigational products (IPs) will be packed as per Good Manufacturing Practice 
(GMP) guidelines. The IP kits will be packed as per the visit schedule to cover the treatment 
duration. The individual subject kit will, at a minimum, be labeled as per FDA guidance.  
The Study Monitor should be notified immediately of the details of any supplies that are 
inadvertently damaged or unaccountable for any reason. These will be documented on drug 
accountability logs that will be collected by the Study Monitor at the end of the study. 
10.3 
Allocation to Treatment Groups 
Subjects will be assigned to 1 of the 3 treatment groups in a 4:1:1 ratio based on a 
computer-generated randomization scheme that will be reviewed and approved by an 
independent statistician. The randomization will be stratified by study site. The randomization 
scheme and treatment allocation for each subject will be included in the final clinical study 
report (CSR) for this study. 
Glenmark  
CONFIDENTIAL 
Page 38 of 91 

GSP 301-303 
GPL/CT/2014/018/III  
Version 2.0 
 
Date 31-Aug-2016 
10.4 
Blinding and Unblinding Procedures 
This study is designed as a double-blind study. The blinding will be maintained by packaging the 
active products and placebo in identical bottles and outer cartons. Additionally, an unblinded 
qualified person not associated with the study team will facilitate the randomization process to 
ensure that the double-blind design of the study is maintained. 
In case of any premature unblinding (e.g., accidental unblinding or unblinding due to a SAE) of 
the IPs, the Investigator should promptly document and explain it to the Sponsor. The Sponsor’s 
medical monitor or delegate should be contacted either prior to opening the code break card or 
soon after, depending on the circumstances. The Investigator will open the code break card for 
the subject under consideration only if knowledge of the randomized treatment is required for the 
treatment of the AE or SAE. In the event of a code break, the following minimum information 
will be recorded in a memo to file, which will be included in the CSR: 
1. Date of the code break 
2. Identification of person(s) requesting the code break 
3. Reason for breaking the code 
4. Investigator's signature 
10.5 
Preparation, Receipt, Storage, Dispensing and Accountability 
The IP should be stored upright between 15° to 25°C (59°F to 77°F) and protected from light. It 
should not be frozen or refrigerated. Subjects will be instructed on the storage conditions for the 
IP. The Investigator (or designee) is responsible for IP accountability at the site and its 
documentation. The Investigator must also ensure that the dispensing and recording of IP is 
conducted only by authorized personnel. The study medication records must be readily available 
for inspection by the Study Monitor and/or auditor/regulatory agency personnel. No medication 
(used or unused) may be returned to the Sponsor, or disposed of at the investigational site, until 
the Sponsor’s Study Monitor has verified/reconciled the accuracy of the study medication 
records at the site and indicated whether the medication should be destroyed at the site or 
returned to the Sponsor. The Study Monitor must indicate the name and address of the individual 
to whom the returned materials should be shipped. 
11 TIMING OF STUDY PROCEDURES AND ASSESSMENTS 
Study procedures and assessments are summarized across all study visits within the Schedule of 
Procedures and Assessments (Appendix 1).  
A focused ENT and eye examination will be done at all visits. If at any visit, clinically 
significant nasal ulceration, nasal mucosal erosion, and nasal septal perforation are observed, or a 
finding at a previous visit has worsened (as judged by the Investigator), the subject should be 
referred to a qualified ENT specialist (medically qualified specialist qualified to evaluate and 
record these conditions, as judged by the Investigator) for further evaluation. A record from the 
specialist should be maintained, including the photographic evidence (imaging of nasal mucosa) 
of the assessment to allow pre- and post-treatment comparisons for AEs (see details in Section 
12.4.11). The Sponsor will collect the de-identified information as part of the study data 
Glenmark  
CONFIDENTIAL 
Page 39 of 91 

GSP 301-303 
GPL/CT/2014/018/III  
Version 2.0 
 
Date 31-Aug-2016 
collection. Eligibility of the subject for participation/continued participation in the study will be 
at the Investigator’s discretion based on whether or not the protocol-defined selection criteria are 
met. These subjects may need to be re-screened due to delay in scheduling an ENT visit to obtain 
the necessary evaluation, as applicable, upon consultation with the Sponsor’s study team and 
approval. A thorough eye examination will also be performed by the Investigator or medically 
qualified designee. 
11.1 
Screening Visit: Visit 1 (Day -7 to -10) 
A Screening Visit (Visit 1) should be scheduled within 7 to 10 days before the Randomization 
Visit (Visit 2). Before any procedures or assessments are performed, the nature of the study and 
the potential risks associated with the study must be explained to each subject and written 
informed consent (and assent as applicable) must be obtained. Once informed consent/assent 
(and Health Insurance Portability and Accountability Act [HIPAA] authorization as applicable) 
has been obtained, the following procedures and evaluations will be performed:  
1. Inclusion/Exclusion criteria  
2. Demographic data 
3. Medical and treatment history  
4. Concomitant medication evaluation 
5. Physical examination 
6. Vital signs  
7. Height and weight 
8. Clinical laboratory investigations (hematology, biochemistry, urinalysis) 
9. Focused ENT and eye examination 
10. Allergen testing (if required)  
11. A 12-lead electrocardiogram (ECG) 
12. Urine pregnancy test, if applicable 
13. Review instructions and provide training on the proper use of the NS using the placebo bottle 
provided in the IP kit provided for the run-in period 
14. Priming and dispensation and administration of single-blind GSP 301 placebo NS pH
at 
the clinic 
15. Distribution of the AR Assessment Diary  
16. Subject assessment of AR symptoms and recording 
17. AE query, if applicable 
Subjects, who fail Screening based on any single criterion at the Screening Visit (Visit 1) where 
there is the prospect of their subsequently becoming eligible, may be re-screened on 1 occasion, 
dependent upon consultation with the Sponsor study team or designee. The subject may not be 
re-screened if the Investigator or the Sponsor determines that the failed criterion may impact the 
efficacy and/or safety assessments. However, subjects who have entered the single-blind, 
Glenmark  
CONFIDENTIAL 
Page 40 of 91 

*63
*3/&7,,,
9HUVLRQ

'DWH$XJ 
SODFHERUXQLQSHULRGDQGWKHQIDLOWRPHHWUDQGRPL]DWLRQFULWHULDIRUDQ\UHDVRQDUHQRWHOLJLEOH
IRUUHVFUHHQLQJWRDYRLGDQ\XQGXHELDV

5DQGRPL]DWLRQ9LVLW9LVLW'D\
7KHIROORZLQJSURFHGXUHVDQGHYDOXDWLRQVZLOOEHSHUIRUPHGDWWKLVYLVLW
 'LVWULEXWLRQRI54/46UHYLHZLQVWUXFWLRQVZLWKWKHVXEMHFWDQGVXEMHFWFRPSOHWLRQRI
54/46
 5&$7
 &RQFRPLWDQWPHGLFDWLRQHYDOXDWLRQ
 9LWDOVLJQV
 )RFXVHG(17DQGH\HH[DPLQDWLRQ
 8ULQHSUHJQDQF\WHVWLIDSSOLFDEOH
 5HYLHZLQVWUXFWLRQVDQGSURYLGHWUDLQLQJRQWKHSURSHUXVHRIWKH16
 &ROOHFWLRQUHYLHZRIWKH$5$VVHVVPHQW'LDU\
 'LVWULEXWLRQRIWKH$5$VVHVVPHQW'LDU\
3K\VLFLDQDVVHVVPHQWRIQDVDOV\PSWRPVHYHULW\DWWKHFOLQLFDOVLWH
 5HYLHZUDQGRPL]DWLRQFULWHULD
 5DQGRPL]DWLRQWUHDWPHQWDVVLJQPHQW
5HWXUQRIVLQJOHEOLQGSODFHERUXQLQVWXG\PHGLFDWLRQ
 3ULPHDQGGLVSHQVDWLRQRIGRXEOHEOLQGVWXG\PHGLFDWLRQ
$GPLQLVWUDWLRQRIGRXEOHEOLQGVWXG\PHGLFDWLRQXQGHUWKHVXSHUYLVLRQRIWKHVWXG\
SHUVRQQHO
$(TXHU\LIDSSOLFDEOH
6XEMHFWFRPSOLDQFHFKHFNVWXG\SURFHGXUHV$5$VVHVVPHQW'LDU\DQGVWXG\PHGLFDWLRQ
7KLVPXVWEHWKHILUVWSURFHGXUHSHUIRUPHG6XEMHFWVUHWXUQLQJIRUWKH5DQGRPL]DWLRQ9LVLW
XQGHUJR54/46DQG5&$7DVVHVVPHQWVDVDSSOLFDEOHEHIRUHFRQILUPDWLRQIRUUDQGRPL]DWLRQ
LQWKHVWXG\,IWKHVXEMHFWIDLOVUDQGRPL]DWLRQFULWHULDIRUDQ\UHDVRQWKHGDWDFROOHFWHGIRUWKH
54/46DQG5&$7ZLOOQRWEHDQDO\]HG6XEMHFWVWKDWIDLOWREHUDQGRPL]HGDWDQ\WLPHGXULQJ
9LVLWZLOOEHGLVFKDUJHGIURPWKHVWXG\IROORZLQJFROOHFWLRQRIWKH54/46DQG5&$7DV
DSSOLFDEOHUXQLQVWXG\PHGLFDWLRQDQGUXQLQGLDU\DVZHOODVDGLVFXVVLRQRI$(VDQG
FRQFRPLWDQWPHGLFDWLRQVDQGRWKHUVDIHW\UHODWHGSURFHGXUHVDVQHHGHGDWWKHGLVFUHWLRQRIWKH
,QYHVWLJDWRU+RZHYHUWKHUHPDLQLQJHIILFDF\UHODWHGDVVHVVPHQWVRXWOLQHGIRUWKLVYLVLWPD\QRW
EHQHHGHGIRUWKHVXEMHFWVZKRIDLOUDQGRPL]DWLRQFULWHULD
2QWKHILUVWGD\RIWUHDWPHQW5DQGRPL]DWLRQ9LVLW>9LVLW@VXEMHFWVZLOOEHLQVWUXFWHGKRZWR
VHOIDGPLQLVWHUVWXG\PHGLFDWLRQZKLOHWKHILUVWGRVHLVWDNHQDWWKHFOLQLF6XEMHFWVZLOO
VHOIDGPLQLVWHUVWXG\PHGLFDWLRQ
DWKRPHGXULQJWKHWUHDWPHQWSHULRG:HHNV
'XULQJWKHWUHDWPHQWSHULRGVXEMHFWVZLOODVVHVVWKHLUV\PSWRPV DQGFRPSOHWHWKH$5
$VVHVVPHQW'LDU\HYHU\PRUQLQJ$0
*OHQPDUN
&21),'(17,$/
3DJHRI
\ S
S

GSP 301-303 
GPL/CT/2014/018/III  
Version 2.0 
 
Date 31-Aug-2016 
o
11.3 
Treatment Visit: Visit 3 (Week 3 ±3 Days) 
The following procedures and evaluations will be performed at this visit: 
1. Concomitant medication evaluation 
2. Focused ENT and eye examination 
3. Urine pregnancy test, if applicable 
4. Review instructions and provide training on the proper use of the NS 
5. Collection/review of the AR Assessment Diary 
6. Distribution of the AR Assessment Diary 
7. Physician assessment of nasal symptom severity at the clinical site 
8. Return of used double-blind study medication to the clinic 
9. Prime and dispensation of double-blind study medication, as applicable 
10. AE query, if applicable 
11. Subject compliance check (study procedures, AR Assessment Diary, and study medication) 
11.4 
Treatment Visit: Visit 4 (Week 6 ±3 Days) 
The following procedures and evaluations will be performed at this visit: 
1. Distribution of RQLQ(S), review instructions with the subject, and subject completion of 
RQLQ(S). This must be the first procedure performed.  
2. RCAT 
3. Concomitant medication evaluation 
4. Focused ENT and eye examination  
5. Urine pregnancy test, if applicable 
6. Review instructions and provide training on the proper use of the NS 
7. Collection/review of the AR Assessment Diary 
8. Distribution of the AR Assessment Diary 
9. Physician assessment of nasal symptom severity at the clinical site 
10. Return of used double-blind study medication to the clinic 
11. Prime and dispensation of double-blind study medication, as applicable 
12. AE query, if applicable. 
13. Subject compliance check (study procedures, AR Assessment Diary, and study medication). 
Glenmark  
CONFIDENTIAL 
Page 42 of 91 

GSP 301-303 
GPL/CT/2014/018/III  
Version 2.0 
 
Date 31-Aug-2016 
11.5 
Treatment Visit: Visit 5 (Week 12 ±5 Days) 
The following procedures and evaluations will be performed at this visit: 
1. Concomitant medication evaluation 
2. Focused ENT and eye examination 
3. Urine pregnancy test, if applicable 
4. Review instructions and provide training on the proper use of the NS 
5. Collection/review of the AR Assessment Diary 
6. Distribution of the AR Assessment Diary 
7. Physician assessment of nasal symptom severity at the clinical site 
8. Return of used double-blind study medication to the clinic 
9. Prime and dispensation of double-blind study medication, as applicable 
10. AE query, if applicable 
11. Subject compliance check (study procedures, AR Assessment Diary, and study medication) 
11.6 
Treatment Visit: Visit 6 (Week 18 ±7 Days) 
The following procedures and evaluations will be performed at this visit: 
1. Concomitant medication evaluation 
2. Focused ENT and eye examination 
3. Urine pregnancy test, if applicable 
4. Review instructions and provide training on the proper use of the NS 
5. Collection/review of the AR Assessment Diary 
6. Distribution of the AR Assessment Diary 
7. Physician assessment of nasal symptom severity at the clinical site 
8. Return of used double-blind study medication to the clinic 
9. Prime and dispensation of double-blind study medication, as applicable 
10. AE query, if applicable 
11. Subject compliance check (study procedures, AR Assessment Diary, and study medication) 
11.7 
Treatment Visit: Visit 7 (Week 24 ±7 Days) 
The following procedures and evaluations will be performed at this visit: 
1. Concomitant medication evaluation 
2. Focused ENT and eye examination 
3. Urine pregnancy test, if applicable 
4. Review instructions and provide training on the proper use of the NS 
Glenmark  
CONFIDENTIAL 
Page 43 of 91 

GSP 301-303 
GPL/CT/2014/018/III  
Version 2.0 
 
Date 31-Aug-2016 
5. Collection/review of the AR Assessment Diary 
6. Distribution of the AR Assessment Diary 
7. Physician assessment of nasal symptom severity at the clinical site 
8. Return of used double-blind study medication to the clinic 
9. Prime and dispensation of double-blind study medication, as applicable 
10. AE query, if applicable 
11. Subject compliance check (study procedures, AR Assessment Diary, and study medication) 
11.8 
Treatment Visit: Visit 8 (Week 30 ±7 Days) 
The following procedures and evaluations will be performed at this visit: 
1. Distribution of RQLQ(S), review instructions with the subject, and subject completion of 
RQLQ(S). This must be the first procedure performed. 
2. RCAT 
3. Concomitant medication evaluation 
4. Physical examination 
5. Vital signs 
6. Height and weight 
7. Clinical laboratory investigations (hematology, biochemistry, urinalysis) 
8. Focused ENT and eye examination 
9. Urine pregnancy test, if applicable 
10. Review instructions and provide training on the proper use of the NS 
11. Collection/review of the AR Assessment Diary 
12. Distribution of the AR Assessment Diary 
13. Physician assessment of nasal symptom severity at the clinical site 
14. Return of used double-blind study medication to the clinic 
15. Prime and dispensation of double-blind study medication, as applicable 
16. AE query, if applicable 
17. Subject compliance check (study procedures, AR Assessment Diary, and study medication) 
11.9 
Treatment Visit: Visit 9 (Week 36 ±7 Days) 
The following procedures and evaluations will be performed at this visit: 
1. Concomitant medication evaluation 
2. Focused ENT and eye examination 
3. Urine pregnancy test, if applicable 
Glenmark  
CONFIDENTIAL 
Page 44 of 91 

GSP 301-303 
GPL/CT/2014/018/III  
Version 2.0 
 
Date 31-Aug-2016 
4. Review instructions and provide training on the proper use of the NS 
5. Collection/review of the AR Assessment Diary 
6. Distribution of the AR Assessment Diary 
7. Physician assessment of nasal symptom severity at the clinical site 
8. Return of used double-blind study medication to the clinic 
9. Prime and dispensation of double-blind study medication, as applicable 
10. AE query, if applicable 
11. Subject compliance check (study procedures, AR Assessment Diary, and study medication) 
11.10 Treatment Visit: Visit 10 (Week 42 ±7 Days) 
The following procedures and evaluations will be performed at this visit: 
1. Concomitant medication evaluation 
2. Focused ENT and eye examination 
3. Urine pregnancy test, if applicable 
4. Review instructions and provide training on the proper use of the NS 
5. Collection/review of the AR Assessment Diary 
6. Distribution of the AR Assessment Diary 
7. Physician assessment of nasal symptom severity at the clinical site 
8. Return of used double-blind study medication to the clinic 
9. Prime and dispensation of double-blind study medication, as applicable 
10. AE query, if applicable 
11. Subject compliance check (study procedures, AR Assessment Diary, and study medication) 
11.11 Treatment Visit: Visit 11 (Week 48 ±7 Days) 
The following procedures and evaluations will be performed at this visit: 
1. Concomitant medication evaluation 
2. Focused ENT and eye examination 
3. Urine pregnancy test, if applicable 
4. Review instructions and provide training on the proper use of the NS 
5. Collection/review of the AR Assessment Diary 
6. Distribution of the AR Assessment Diary 
7. Physician assessment of nasal symptom severity at the clinical site 
8. Return of used double-blind study medication to the clinic 
9. Prime and dispensation of double-blind study medication, as applicable 
Glenmark  
CONFIDENTIAL 
Page 45 of 91 

GSP 301-303 
GPL/CT/2014/018/III  
Version 2.0 
 
Date 31-Aug-2016 
10. AE query, if applicable 
11. Subject compliance check (study procedures, AR Assessment Diary, and study medication) 
11.12 Final Visit: Visit 12 (Week 52 + 10 Days) 
The following procedures and evaluations will be performed at this visit: 
1. Distribution of RQLQ(S), review instructions with the subject, and subject completion of 
RQLQ(S). This must be the first procedure performed. 
2. RCAT 
3. Concomitant medication evaluation 
4. Physical examination 
5. Vital signs 
6. Height and weight 
7. Clinical laboratory investigations (hematology, biochemistry, urinalysis) 
8. Focused ENT and eye examination 
9. A 12-lead ECG 
10. Urine pregnancy test, if applicable 
11. Collection/review of the AR Assessment Diary 
12. Physician assessment of nasal symptom severity at the clinical site 
13. Return of used double-blind study medication to the clinic 
14. AE query, if applicable 
15. Subject compliance check (study procedures, AR Assessment Diary, and study medication) 
11.13 Discontinuation Visit  
The process to be followed for a subject who discontinues treatment or withdraws from the study 
is described in Section 9.4. If at any time point, a subject is deemed ineligible to continue in the 
study, the Final Visit/Discontinuation Visit (Visit 12) procedures will be conducted and recorded 
in the Early Withdrawal/Termination/Discontinuation pages of the CRF/eCRF. After completion 
of study participation, the subject will be treated, as needed, at the discretion of the Investigator. 
Every effort should be made to contact the subject for a follow-up if the subject has not returned 
to the clinic for scheduled visits (lost-to-follow up subject) to ensure the safety of the subject. 
If the subject is withdrawn because of an AE, the AE will be followed until the medical 
condition returns to baseline or is considered stable or chronic. The Sponsor (or designee) should 
be informed of all subjects withdrawn/discontinued for this reason. If there are multiple reasons 
for early withdrawal/discontinuation, the worst case scenario should be chosen.   
11.14 Unscheduled Visit 
An unscheduled visit (or telephone contact) may be performed at any time during the study at the 
subject’s request or as deemed necessary by the Investigator. The date and reason for the 
Glenmark  
CONFIDENTIAL 
Page 46 of 91 

GSP 301-303 
GPL/CT/2014/018/III  
Version 2.0 
 
Date 31-Aug-2016 
unscheduled visit will be recorded on the CRF/eCRF as well as any other data obtained (e.g., 
AEs, concomitant medications/treatments, and results from procedures or tests). 
11.15 Follow-Up Visit 
No Follow-up Visit is planned during the study. 
12 STUDY PROCEDURES AND ASSESSMENTS 
12.1 
Demography and Other Pretreatment Assessments 
Subject demographic information will be collected at the Screening Visit (Visit 1). Demographic 
information includes date of birth (or age), sex, race/ethnicity, and any other study-specific 
demography. Allergen testing data will be recorded in the source documents and CRF/eCRF with 
the description of the allergen. 
Medical and surgical history and current medical conditions will be recorded at the Screening 
Visit (Visit 1). All relevant medical and surgical history within 2 years must be noted in the 
Medical History and Current Medical Conditions CRF/eCRF.  
Other baseline and pretreatment assessments will be performed as designated in the Schedule of 
Procedures and Assessments (Appendix 1).  
12.2 
Efficacy Assessments 
The primary objective of the study is to evaluate the long-term safety of GSP 301 NS. However, 
the long-term efficacy will also be evaluated. 
12.2.1 
Subject-Reported Nasal Symptoms   
An efficacy measure in this study is the subject-reported Total Nasal Symptom Score (TNSS). 
The TNSS is defined as the sum of the subject-reported symptom scores for 
 The subjec will a ess 
and report his/her nasal symptoms in the morning (AM assessment) on each day of the placebo 
run-in and double-blind treatment periods prior to administering the study treatment. The subject 
will record the scores for each symptom in an AR Assessment Diary. The AM assessment should 
be performed prior to bathing, consumption of food or beverages, or strenuous activities. The 
morning dose of study medication should be administered immediately after completion of the 
AR Assessment Diary. 
The subject will be asked to assess both reflective (i.e., an evaluation of symptom severity over 
the past 24 hours prior to the recording of the score) and instan aneous (i.e., an evaluation of the 
symptom severity just before taking study medication 
 nasal symptoms. 
Each of the following symptoms will be assessed. 
Nasal Symptoms 
1. Nasal Congestion 
2. Rhinorrhea (Runny Nose) 
3. Nasal Itching 
4. Sneezing 
Each of the above symptoms will be rated on a 4-point severity scale as follows: 
Glenmark  
CONFIDENTIAL 
Page 47 of 91 

GSP 301-303 
GPL/CT/2014/018/III  
Version 2.0 
 
Date 31-Aug-2016 
Score 
Grade 
Description 
0 
Absent 
No sign/symptom evident 
1 
Mild 
Signs/symptoms clearly present but minimal awareness; easily tolerated 
2 
Moderate 
Definite awareness of signs/symptoms which are bothersome but tolerable 
3 
Severe 
Signs/symptoms are hard to tolerate; cause interference with activities of daily 
living and/or sleeping 
The subject will not assess AR symptoms in the evening. Howeve , e s
ect will 
self-administer study medication in the evening
. 
12.2.2 
Physician Assessment of Nasal Symptom Severity 
The PNSS will be derived from the intensity of the following nasal symptoms associated with 
AR: rhinorrhea (runny nose), nasal congestion, nasal itching, and sneezing.16 Clinicians will 
assess the severity of the above symptoms based on questioning the subjects (overall feeling 
since last visit), the ENT and eye examination, and other observations. 
Whenever possible, the same medically qualified person should complete this assessment for the 
same subject throughout that subject’s participation in this study. 
12.2.3 
Rhinoconjunctivitis Quality of Life Questionnaire - Standardized Activities 
The RQLQ(S) (Appendix 4) used in this study is a disease-specific, validated, quality-of-life 
(QOL) questionnaire developed to measure the functional problems (physical, emotional, and 
social) that are troublesome to adults and adolescents (aged ≥12 years) with allergies. The 
RQLQ(S) measures both atopic and non-atopic experiences as a result of subjects’ nasal and 
ocular symptoms. 
The RQLQ(S) has 28 questions in 7 domains (activities, sleep, non-nose/eye symptoms, practical 
problems, nasal symptoms, eye symptoms, and emotional).17 The subject is asked to recall their 
experiences during the previous week and to give responses on a 7-point scale (0=not troubled to 
6=extremely troubled) for the domains of activities, sleep, non-nose/eye symptoms, practical 
problems, nasal symptoms, and eye symptoms. The domain “emotional” utilizes a 7-point scale 
(0=none of the time to 6=all of the time). This questionnaire should be completed as the first 
activity of visits that include this assessment.  
The self-administered version of the RQLQ(S) will be completed by the subject at the 
investigational site at the Randomization Visit (Visit 2), Treatment Visit 4 (Week 6), Treatment 
Visit 8 (Week 30), and the Final Visit/Discontinuation Visit (Visit 12 at Week 52). The 
RQLQ(S) administration must be the first procedure conducted at these study visits. 
The study site personnel and the Investigators will be provided with detailed instructions for 
conducting QOL assessments in order to achieve maximum compliance with the standards of 
QOL assessments in a clinical study environment and to maximize data quality. Caregivers or 
study site personnel are not allowed to interfere or communicate with the subject completing the 
questionnaire over and above re-stating the question(s) on the questionnaire exactly as written. 
Completion of the questionnaire may take approximately 10 minutes depending on the 
experience and capability of the individual completing the questionnaire. After completion of the 
RQLQ(S), the site personnel will check the questionnaire for completeness and legibility. 
Glenmark  
CONFIDENTIAL 
Page 48 of 91 

GSP 301-303 
GPL/CT/2014/018/III  
Version 2.0 
 
Date 31-Aug-2016 
An English-language version of the RQLQ(S) will be provided to all subjects who provide 
informed consent in English. However, if a subject consents in a language other than English, the 
RQLQ(S) will be provided to the subject in that language if a validated version of the RQLQ(S) 
is available. If a validated version of the RQLQ(S) is not available in that language, then the 
subject will be exempt from completing the RQLQ(S). 
12.2.4 
Rhinitis Control Assessment Test 
The RCAT (Appendix 5) is a brief, patient-completed tool to evaluate rhinitis symptom 
control.18 This questionnaire asks the subject about nasal and other allergy symptoms that are not 
related to a cold or flu, and the control of these symptoms over the past week. Responses to the 
questions are scored by the number next to the response box. The total RCAT score is calculated 
by adding individual RCAT item or domain scores. The total RCAT score can range from 6 to 
30. 
An English-language version of the RCAT will be provided to all subjects who provide informed 
consent in English. However, if a subject consents in a language other than English, the RCAT 
will be provided to the subject in that language if a validated version of the RCAT is available. If 
a validated version of the RCAT is not available in that language, then the subject will be exempt 
from completing the RCAT. 
12.3 
Pharmacokinetic, Pharmacodynamic, Biomarker and Pharmacogenomic 
Assessments 
Not applicable. 
12.4 
Safety Assessments 
Safety assessments will consist of monitoring and recording all AEs, (including severity as mild, 
moderate and severe as per Section 12.4.1.2), and SAEs; regular monitoring of hematology, 
biochemistry, and urinalysis values (as applicable per the protocol or for safety reasons); periodic 
measurement of vital signs and ECGs; and physical examinations as detailed in the Schedule of 
Procedures and Assessments (Appendix 1). Additional details on the safety procedures 
performed in the study are detailed below. 
Any abnormal laboratory test result (hematology, biochemistry, or urinalysis) or other safety 
assessment (eg, 12-lead ECGs, radiological scans, vital signs measurements), including any that 
worsen from baseline, that is considered to be clinically significant in the medical and scientific 
judgment of the Investigator will be recorded as an AE or SAE. 
However, any clinically significant safety assessment that is associated with the underlying 
disease, unless judged by the Investigator to be more severe than expected for the subject’s 
condition, will not be reported as an AE or SAE. 
12.4.1 
Adverse Events  
The Investigator or site staff will be responsible for detecting, documenting, and reporting events 
that meet the definition of an AE or SAE. 
The reference safety information for this study is the IB Section 6.4.8.2 Reference Safety 
Information within the Summary of Data and Guidance for Investigators.  
Glenmark  
CONFIDENTIAL 
Page 49 of 91 

GSP 301-303 
GPL/CT/2014/018/III  
Version 2.0 
 
Date 31-Aug-2016 
12.4.1.1 
Adverse Events 
An AE is defined as any untoward medical occurrence in a subject administered IP that does not 
necessarily have a causal relationship with the treatment. An AE can, therefore, be any 
unfavorable and unintended sign (including an abnormal laboratory finding), symptom or disease 
(new or exacerbated) temporally associated with the use of an IP, whether or not related to the 
IP. An AE includes any event, regardless of the presumed causality between the event and the IP.  
Events that, while not necessarily meeting the definition of AEs, should be treated as such 
because they may be reportable to Regulatory Authorities according to AE reporting regulations, 
whether or not considered causally associated with IP, include the following: 
• IP overdose, whether accidental or intentional. 
• IP abuse. 
• An event occurring from IP withdrawal. 
• Inadvertent or accidental IP exposure (e.g., product leaking or being spilled onto a subject 
or care-giver). 
• Unexpected therapeutic or clinical benefit from the IP.  
• Medication errors (i.e., incorrect route of administration, incorrect dosage, use of 
incorrect product).  
Events that do not meet the definition of an AE include: 
• Medical or surgical procedure (e.g., endoscopy, appendectomy); the condition that led to 
the procedure is an AE. 
• Situations where an untoward medical occurrence did not occur (social and/or 
convenience admission to a hospital). 
• Anticipated day-to-day fluctuations of pre-existing disease(s) or condition(s) present or 
detected at the start of the study that do not worsen. 
• The disease/disorder being studied or expected progression, signs or symptoms of the 
disease/disorder being studied, unless more severe than expected for the subject’s 
condition. 
12.4.1.2 
Assessment of Severity of Adverse Events 
The severity of AEs is classified as follows: 
Mild:  
The AE is a transient discomfort and does not interfere in a significant manner 
with the subject. 
The AE resolves spontaneously or may require minimal therapeutic intervention. 
Moderate:  
The AE produces limited impairment of function and may require therapeutic 
intervention. 
The AE produces no sequelae. 
Glenmark  
CONFIDENTIAL 
Page 50 of 91 

GSP 301-303 
GPL/CT/2014/018/III  
Version 2.0 
 
Date 31-Aug-2016 
Severe: 
The AE results in a marked impairment of function and may lead to temporary 
inability to resume usual life pattern. 
The AE produces sequelae which require (prolonged) therapeutic intervention. 
The criteria for assessing severity are different from those used for seriousness (see 
Section 12.4.2 for the definition of a SAE). 
12.4.1.3 
Assessment of Relationship to Study Medication 
The relationship of AEs to study medication is classified as follows: 
Not Related: 
A causal relationship between the study treatment and the AE is not a reasonable 
possibility 
Related: 
A causal relationship between the study treatment and the AE is a reasonable 
possibility  
Items to be considered when assessing the relationship of an AE to the study treatment are: 
• Temporal relationship of the onset of the event to the initiation of the study treatment 
• The course of the event, especially the effect of discontinuation of study treatment or 
reintroduction of study treatment, as applicable 
• Whether the event is known to be associated with the study treatment or with other 
similar treatments 
• The presence of risk factors in the study subject known to increase the occurrence of the 
event 
• The presence of non-study treatment-related factors that are known to be associated with 
the occurrence of the event 
For each AE, the Investigator should answer the following question with Yes or No: 
• Was there a reasonable possibility (evidence) that the drug caused the adverse event?  
A reasonable possibility means that there are facts (evidence) or arguments to suggest a causal 
relationship. 
NOTE: For subjects that have not started receiving study medication (run-in or double-blind), the 
answer must be no. 
12.4.2 
Serious Adverse Events  
A SAE is any untoward medical occurrence that, at any dose: 
• Results in death. 
• Is life-threatening. 
NOTE: The term 'life-threatening' in the definition of 'serious' refers to an event in which 
the subject was at risk of death at the time of the event. It does not refer to an event, 
which hypothetically might have caused death, if it were more severe. 
Glenmark  
CONFIDENTIAL 
Page 51 of 91 

GSP 301-303 
GPL/CT/2014/018/III  
Version 2.0 
 
Date 31-Aug-2016 
• Requires hospitalization or prolongation of existing hospitalization. 
NOTE: In general, hospitalization signifies that the subject has been detained (usually 
involving at least an overnight stay) at the hospital or emergency ward for observation 
and/or treatment that would not have been appropriate in the physician’s office or 
outpatient setting. Complications that occur during hospitalization are AEs. If a 
complication prolongs hospitalization or fulfills any other serious criteria, the event is 
serious. When in doubt as to whether “hospitalization” occurred or was necessary, the AE 
should be considered serious. Hospitalization for elective treatment of a pre-existing 
condition that did not worsen from baseline is not considered an AE. 
• Results in disability/incapacity. 
NOTE: The term disability means a substantial disruption of a person’s ability to conduct 
normal life functions. This definition is not intended to include experiences of relatively 
minor medical significance such as uncomplicated headache, nausea, vomiting, diarrhea, 
influenza, and accidental trauma (e.g., sprained ankle) that may interfere or prevent 
everyday life functions but do not constitute a substantial disruption. 
• Is a congenital anomaly/birth defect. 
• Medical or scientific judgment should be exercised in deciding whether reporting is 
appropriate in other situations, such as important medical events that may not be 
immediately life-threatening or result in death or hospitalization but may jeopardize the 
subject or may require medical or surgical intervention to prevent 1 of the other outcomes 
listed in the above definition. These should also be considered serious. Examples of such 
events are invasive or malignant cancers, intensive treatment in an emergency room or at 
home for allergic bronchospasm, blood dyscrasias or convulsions that do not result in 
hospitalization, or development of drug dependency or drug abuse. 
Prompt notification of SAEs by the Investigator to the Sponsor is essential so that ethical 
responsibilities and both regulatory and legal obligations towards the safety of subjects are met. 
The Sponsor has a legal responsibility to notify both the local regulatory authority and other 
regulatory agencies about the safety of a product under clinical investigation. The Sponsor will 
comply with country-specific regulatory requirements relating to safety reporting to the 
regulatory authority, IRB/ IEC and Investigators. 
A SAE must be reported to the Sponsor immediately or within 24 hours of the Investigator or 
site staff becoming aware of the event. Reporting should be performed by recording as much 
information as available at the time on the SAE Form and sending it to the contact information 
provided below:  
Fax:  + 44 1923 251137 
Email:  GlobalClinicalSAE@glenmarkpharma.com 
 
When further information becomes available, the SAE Form should be updated with the new 
information and reported immediately using the same contact information. Follow-up reports 
must be submitted to the Sponsor until the event resolves, the event stabilizes or the event returns 
to baseline if a baseline value is available. 
Glenmark  
CONFIDENTIAL 
Page 52 of 91 

GSP 301-303 
GPL/CT/2014/018/III  
Version 2.0 
 
Date 31-Aug-2016 
Additional information will be requested by the Sponsor, as necessary. 
12.4.3 
Pregnancy 
Any subject who has a positive pregnancy test after signing the informed consent form (ICF) 
should be withdrawn from the study immediately and study medication should be discontinued 
immediately. 
Any pregnancy that occurs during study participation must be reported to the Sponsor, using a 
Clinical Study Pregnancy Form, immediately or within 24 hours of the Investigator learning of 
its occurrence. The report should contain as much information as possible and should be sent to:  
Fax:  + 44 1923 251137 
Email:  GlobalClinicalSAE@glenmarkpharma.com 
When further information becomes available, the Clinical Study Pregnancy Form should be 
updated with all new information and reported immediately using the same contact information 
above.  The pregnancy must be followed up to determine the outcome (including premature 
termination) and status of mother and child, and this information must be sent to the Sponsor as 
above. Pregnancy complications and elective terminations for medical reasons must be reported 
as an AE or SAE.  Spontaneous abortions must be reported as an SAE. 
Additional information will be requested by the Sponsor as necessary. 
Any SAE that occurs in association with a pregnancy that is brought to the Investigator’s 
attention after the subject has completed the study, and is considered by the Investigator as 
possibly related to the investigational product, must be promptly reported to the Sponsor. 
The Investigator must attempt to collect pregnancy information on any female partner, of a male 
study subject, who becomes pregnant while the male partner is participating in this study. The 
Investigator must record pregnancy information on the appropriate form and submit it to the 
Sponsor within 2 weeks of learning of the partner’s pregnancy. The partner must also be 
followed up to determine the outcome of the pregnancy. Information on the status of the mother 
and child must be forwarded to the Sponsor. Generally, follow-up will be no longer than 6 to 
8 weeks following the estimated delivery date. Any premature termination of the pregnancy must 
be reported. 
12.4.4 
Adverse Events of Special Interest 
Not applicable. 
12.4.5 
Collection and Recording of Adverse Events and Serious Adverse Events 
The Investigator or site staff is responsible for detecting, documenting, and reporting events that 
meet the definition of an AE or SAE. 
Adverse events will be collected from the time of signing the ICF until the last contact.  
Serious adverse events will be collected over the same time period as stated above for AEs. 
However, any SAEs assessed as related to study participation (e.g., IP, protocol mandated 
procedures, invasive tests, or change in existing therapy) or related to a concomitant medication 
that is a Sponsor product will be recorded from the time a subject consents to participate in the 
Glenmark  
CONFIDENTIAL 
Page 53 of 91 

GSP 301-303 
GPL/CT/2014/018/III  
Version 2.0 
 
Date 31-Aug-2016 
study up to and including any follow-up contact. All SAEs will be reported to the Sponsor within 
24 hours, as indicated in Section 12.4.2. 
The Investigator will enquire about the occurrence of AEs/SAEs at every visit throughout the 
study (including Follow-up and Discontinuation visits where applicable) by asking the following 
non-leading verbal question of the subject (or care-giver, where appropriate): 
• “Have you had any medical problems since your last visit?” 
All AEs not resolved by the end of the study or that have not resolved upon the subject’s 
discontinuation in the study must be followed until the event resolves, the event stabilizes, or the 
event returns to baseline if a baseline value is available. 
All AEs regardless of seriousness, severity, or relationship to the study medication must be 
recorded on the AE pages of the CRFs/eCRFs.  
Adverse events that meet the definition of a SAE must be reported on the SAE Form provided 
for this study. 
Adverse events must be documented in clear, unambiguous medical language. Do not use 
abbreviations or acronyms.  
For each AE, record only the diagnosis; do not report the characteristic signs and symptoms of 
the diagnosis as additional AEs.  
If a diagnosis is unavailable, each sign and symptom should be recorded as an AE. Update the 
AE CRF/eCRF record with the relevant diagnosis alone, when this is available. 
In general, abnormal findings at screening should be recorded in the subject’s Medical History or 
in the Concurrent Conditions section in the CRF/eCRF. However if, in the Investigator’s 
opinion, the finding is clinically significant and represents a condition that was not present at the 
signing of informed consent, then the finding must be reported as an AE. 
12.4.6 
Clinical Laboratory Tests 
Subjects should be in a seated or supine position during blood collection. The Schedule of 
Procedures and Assessments (Appendix 1) shows the visits and time points at which blood for 
clinical laboratory tests and urine for urinalysis will be collected in the study. Lists of clinical 
laboratory tests are provided in Appendix 3 List of Clinical Laboratory Tests. A central 
laboratory will be used to measure laboratory parameters that are part of the safety assessments. 
12.4.7 
Urine Pregnancy Testing 
Urine pregnancy testing will be completed by a dipstick evaluation at the Investigator’s clinical 
facility for all female subjects of childbearing potential as designated in the Schedules of 
Procedures and Assessments (Appendix 1) or as indicated by the subject’s condition. The testing, 
based on beta human chorionic gonadotropin (β-HCG), will be carried out as per the 
manufacturer’s instructions. 
A positive finding during the Screening Visit (Visit 1) will prevent the subject from study 
participation, and a positive finding at or after Randomization Visit (Visit 2) will require 
immediate Sponsor notification, discontinuation of study medication, and termination from the 
study. 
Glenmark  
CONFIDENTIAL 
Page 54 of 91 

GSP 301-303 
GPL/CT/2014/018/III  
Version 2.0 
 
Date 31-Aug-2016 
12.4.8 
Vital signs 
Vital signs evaluation will be performed as designated in the Schedule of Procedures and 
Assessments (Appendix 1). Vital sign evaluations will include sitting blood pressure (mm Hg) 
and pulse rate (beats/minute) after at least 5 minutes of rest in the seated position. For each 
subject, blood pressure measurements will be taken from the same arm throughout the study. 
Pulse rate will be measured from the radial pulse counted electronically or manually over at least 
15 seconds and adjusted to a per minute value. The methods of assessment should be consistent 
throughout the study for each subject. A medically qualified staff member will perform the vital 
sign evaluations. If a clinically important change in vital signs is observed, the assessment should 
be repeated in 5 to 10 minutes to confirm the change. 
12.4.9 
Electrocardiograms 
Electrocardiograms will be obtained as designated in the Schedule of Procedures and 
Assessments (Appendix 1). Subjects must be in the recumbent or supine position for a period of 
5 minutes prior to the 12-lead ECG. 
An ECG abnormality may meet the criteria of an AE as described in this protocol (see Adverse 
Events, Section 12.4.1) and the CRF/eCRF Completion Guidelines. In these instances, the AE 
corresponding to the ECG abnormality will be recorded on the AE CRF/eCRF. 
For ECG abnormalities that meet criteria for an SAE (Section 12.4.2), the site must fax or email 
the SAE report, including the ECG tracing and report, to the Sponsor using the SAE form. 
12.4.10 
Physical Examinations 
Physical examinations (comprehensive) will be performed as designated in the Schedule of 
Procedures and Assessments (Appendix 1). Documentation of the physical examination will be 
included in the source documentation at the site. Significant findings at the Screening Visit 
(Visit 1) will be recorded on the Medical History and Current Medical Conditions CRF/eCRF. 
Changes from screening physical examination or subsequent findings that meet the definition of 
an AE will be recorded on the AE CRF/eCRF. 
Height (cm) and weight (kg) will also be measured at Screening Visit (Visit 1) and at the Final 
Visit / Discontinuation Visit (Visit 12). 
12.4.11 
Focused Ears, Nose, and Throat and Eye Examinations 
Focused ENT and eye examinations will be performed as designated in the Schedule of 
Procedures and Assessments (Appendix 1). The Investigator or medically qualified designee will 
perform a thorough and focused ENT and eye examination. Whenever possible, the same 
medically qualified person should complete this assessment for the same subject throughout that 
subject’s participation in the study. 
Nasal examinations will be performed to assess signs of AR as well as known complications of 
intranasal corticosteroid or antihistamine use (e.g., bleeding, perforation and ulceration). The 
focused ENT examination will include an evaluation of nasal irritation, epistaxis, and additional 
nasal symptoms, graded according to the criteria provided as follows.  
Glenmark  
CONFIDENTIAL 
Page 55 of 91 

GSP 301-303 
GPL/CT/2014/018/III  
Version 2.0 
 
Date 31-Aug-2016 
Evaluation 
Grading Criteria 
Nasal Irritation 
0= None 
 
Grade 1A = Focal irritation (focal nasal 
inflammation, erythema, or hyperemia) 
 
Grade 1B = Superficial mucosal erosion 
 
Grade 2 = Moderate mucosal erosion 
 
Grade 3 = Ulceration 
 
Grade 4 = Septal perforation 
Epistaxis  
None 
 
Mild = Self-limited 
 
Moderate = Significant, prevents daily activity 
 
Severe = Emergency room visit or hospitalization 
Mucosal Edema, Nasal discharge, 
Mucosal Erythema, , and Crusting of 
Mucosa 
None 
Mild 
Moderate 
Severe 
Note: Epistaxis category may also include mild mucosal bleeding including reports of even a single speck of blood 
on a tissue based on the Investigator’s judgment. However, moderate to severe grading of epistaxis should exclude 
these minor mucosal bleeding cases and should include only significant cases of epistaxis.  
Throat examination will be conducted to evaluate evidence of throat irritation, candidiasis and 
postnasal drip. Any clinically significant new findings, not related to the study indication (PAR), 
evident at any visit after the Screening Visit (Visit 1), as judged by the Investigator, should be 
captured as an AE and reported and recorded in the CRF/eCRF. All findings at the Screening 
Visit (Visit 1) will be captured on the Medical History page of the CRF/eCRF. 
If clinically significant nasal structural abnormalities (as judged by the Investigator) including, 
but not limited to, nasal ulceration, nasal mucosal erosion, and significant septal deviation are 
observed during any visit, the subject should be referred to a qualified ENT specialist or other 
medically qualified specialist (qualified to evaluate and record these conditions, as judged by the 
Investigator) for further evaluation as soon as possible. A record from the specialist should be 
maintained including the photographic evidence (imaging of nasal mucosa) of the assessment to 
allow pre- and post-treatment comparisons for AEs (see details at the beginning of Section 12.4 
and Section 12.4.5). The Sponsor will collect the de-identified information as part of the study 
data collection. Eligibility of the subject for participation in the study will be at the Investigator’s 
discretion based on whether or not the protocol-defined selection criteria are met. 
A thorough eye examination will also be performed by the Investigator or medically qualified 
designee to assess signs of AR as well as any known complications of intranasal corticosteroid or 
antihistamine use. If needed, the subject should be referred to a qualified ophthalmologist for 
further evaluation as soon as possible. 
12.4.12 
Confirmation of Medical Care by Another Physician 
The Investigator will instruct subjects to inform site personnel when they are planning to receive 
medical care by another physician. At each visit, the Investigator will ask the subject whether 
he/she has received medical care by another physician since the last visit or is planning to do so 
in the future. When the subject is going to receive medical care by another physician, the 
Glenmark  
CONFIDENTIAL 
Page 56 of 91 

GSP 301-303 
GPL/CT/2014/018/III  
Version 2.0 
 
Date 31-Aug-2016 
Investigator, with the consent of the subject, will inform the other physician that the subject is 
participating in the clinical study. 
13 DATA ANALYSIS AND STATISTICAL METHODS 
The statistical analysis will be coordinated by the responsible Sponsor biostatistician (or 
designee at the Contract Research Organization [CRO]). A Statistical Analysis Plan (SAP) will 
be written to provide details of the analysis, along with specifications for tables, listings, and 
figures to be produced. The SAP will be finalized before the database lock. If there are 
differences, the information in the SAP will supersede the information in the protocol. Any 
changes from the analyses planned in the SAP will be justified in the CSR. 
All analyses will be performed by the Sponsor (or designee CRO) using SAS® Version 9.3 or 
above. 
In general, all data will be summarized with descriptive statistics (number of subjects, mean, and 
standard deviation [SD], minimum, median and maximum) for continuous endpoints, and 
frequency and percentage for categorical endpoints. 
13.1 
Sample Size  
The sample size of 600 subjects for this study (400 subjects on GSP 301 NS and 100 subjects in 
each of the 2 placebo groups) is based on the ICH E1 Guideline (ICH E1)19 and the FDA 
Guidance on Allergic Rhinitis,14 which requires treatment of at least 300 subjects for 6 months 
and 100 subjects for 1 year. Based on an estimated attrition rate of 25% after 6 months and 50% 
after 52 weeks, 400 subjects in the GSP 301 NS treatment group are considered sufficient to 
meet the above requirements. 
13.2 
Analysis Sets 
Detailed criteria for analysis sets will be documented in the SAP and the allocation of subjects to 
analysis sets will be determined prior to database hard-lock.  
The FAS will consist of all subjects who are randomized and receive at least 1 dose of IP and 
have at least 1 post-baseline efficacy assessment. This will be the primary analysis set for 
efficacy analyses. 
The Per Protocol Set (PPS) will consist of the subset of the FAS who do not meet criteria for 
PPS exclusion. 
The Safety Analysis Set (SAS) will consist of all subjects who took at least 1 dose of study 
medication following randomization and will be used for all safety analyses.  
The RQLQ(S) Analysis Set will consist of all English-speaking subjects ≥18 years old with 
impaired QOL at baseline as defined by a RQLQ(S) score at the Randomization Visit (Visit 2) of 
3.0 or greater. 
13.3 
Subject Disposition 
The subject accountability and disposition information will be summarized by study treatment 
group. The number of subjects screened, treated with study medication during the run-in period, 
randomized, treated with study medication following randomization, and the number of subjects 
Glenmark  
CONFIDENTIAL 
Page 57 of 91 

GSP 301-303 
GPL/CT/2014/018/III  
Version 2.0 
 
Date 31-Aug-2016 
in each analysis set will be tabulated. In addition, completion status and primary reason for 
withdrawal will be summarized by study treatment group.  
13.4 
Demographic and Other Baseline Characteristics 
Demographics and other baseline characteristics will be summarized by treatment group for the 
SAS and other analysis sets as required. Descriptive statistics will include the number of subjects 
and demographic and baseline characteristics such as age, sex, race, and ethnicity.   
13.5 
Efficacy Analyses 
Efficacy analysis will be conducted on the FAS and PPS. The interpretation of results from 
statistical tests will be based on the FAS. The PPS will be used to assess the robustness of the 
results from the statistical tests based on the FAS. 
Efficacy within certain subgroups of clinical interest (e.g., age, sex, race, and ethnicity) will be 
examined. Further details on the subgroups of interest will be specified in the SAP. 
Change from baseline in average AM rTNSS and iTNSS over the first 6, 30, and 52 weeks of 
treatment will be analyzed using an analysis of covariance (ANCOVA) model adjusting for 
study treatment group, site, and baseline (defined as the average of the last 4 consecutive AM 
assessments during the last 4 days of the run-in period from the Day -3 AM assessment to the 
AM assessment on the day of randomization). At least 2 out of 4 assessments (scores) should be 
available in order to calculate the baseline scores for the AM rTNSS and iTNSS (linear, 
continuous covariate). Least squares means (LSMs) of the treatment differences and associated 
95% confidence intervals (95% CIs) and p-values will be presented. A multiple, imputation-
based approach where complete data sets are drawn will be used for handling missing data in the 
efficacy analysis. The imputation model will be defined and fully detailed in the SAP. 
Changes from baseline in rTNSS and iTNSS at the end of each week of treatment and changes 
from baseline in individual nasal symptom scores over the first 6, 30, and 52 weeks (and at the 
end of each treatment week) of the treatment period will be analyzed in a similar manner as 
described above.  
Changes from baseline in RQLQ(S) at Weeks 6, 30, and 52 will be analyzed for the FAS and the 
RQLQ(S) Analysis Set using ANCOVA models adjusting for study treatment group, site, and 
baseline RQLQ(S) (linear, continuous covariate). For subjects who withdraw early from the 
study, the RQLQ(S) score at their discontinuation visit will be used. 
The analyses of RCAT results will be similar to the RQLQ(S) analyses except the RQLQ(S) 
analysis set will not apply. 
Detailed statistical analyses and methods will be provided in the SAP. 
13.6 
Pharmacokinetic, Pharmacodynamic, Biomarker, and 
Pharmacogenomic/Pharmacogenetic Analyses 
Not applicable. 
Glenmark  
CONFIDENTIAL 
Page 58 of 91 

GSP 301-303 
GPL/CT/2014/018/III  
Version 2.0 
 
Date 31-Aug-2016 
13.7 
Safety Analyses 
Unless otherwise specified, ‘baseline’ will be defined as the last available assessment prior to the 
first dose of study medication following randomization. 
13.7.1 
Extent of Exposure 
The number of subjects exposed to each study treatment will be summarized. The number of 
days on treatment and the number of days on study (run-in plus treatment periods) will be 
summarized by study treatment. In addition, treatment compliance will be summarized by 
categories (details will be provided in the SAP) and study treatment. 
13.7.2 
Adverse Events 
Adverse events will be coded using the current Medical Dictionary for Regulatory Activities 
(MedDRA). Adverse events occurring between the signing of informed consent and 
administration of the first dose of randomized study medication will be regarded as pre-treatment 
AEs and included in the subject listings but not in the summary tables. Adverse events occurring 
after the first dose of randomized study medication will be defined as TEAEs.  
The safety endpoints related to AEs are: 
• Proportion of subjects with TEAEs.  
• Proportion of subjects with treatment-related TEAEs. 
• Incidence, type, and severity of the TEAEs after 30 weeks of study treatment. 
• Incidence, type, and severity of the TEAEs after 52 weeks of study treatment.  
The number and percentage of subjects with TEAEs will be summarized by study treatment 
group, overall, and by system organ class (SOC) and preferred term (PT) using frequency counts 
and percentages. The summaries will also include the number of TEAEs experienced. A similar 
summary will be produced for subjects with treatment-related TEAE. 
The number and percentage of subjects with a TEAE that has a start date within 30 weeks of the 
start of treatment (≤182 days) will be summarized by severity and study treatment group, overall, 
and by SOC and PT using frequency counts and percentages. A similar summary will be 
produced including all TEAEs during the study (i.e., after 52 weeks of treatment).  
If sufficient data exist, TEAE frequencies will be compared across treatment groups using 
Fisher’s exact test or a similar test. 
Additionally, the number and percentage of SAEs, TEAEs leading to discontinuation, and 
TEAEs related to the IP will be summarized by SOC, PT, and study treatment group. All AEs 
will be displayed in listings. AEs that occur during the run-in period will be summarized 
separately.  
13.7.3 
Laboratory Data 
The laboratory data (hematology, biochemistry, and urinalysis), will be summarized for each 
visit at which laboratory assessments are done (Screening Visit [Visit 1], Week 30 [Visit 8], and 
Week 52 [Visit 12]). In addition, values outside the normal range and values deemed as 
Glenmark  
CONFIDENTIAL 
Page 59 of 91 

GSP 301-303 
GPL/CT/2014/018/III  
Version 2.0 
 
Date 31-Aug-2016 
clinically significant by the Investigator will be listed. The data will be summarized using 
descriptive statistics. All laboratory data will be displayed in listings. 
13.7.4 
Vital Signs 
Descriptive statistics will be used to summarize vital sign results and changes from baseline by 
treatment group and time point (Week 30 [Visit 8] and Week 52 [Visit 12]). Values of potential 
clinical significance will be defined in the SAP. The number of subjects with values of potential 
clinical significance will be tabulated. All vital signs data will be displayed in listings. 
13.7.5 
Electrocardiograms 
Descriptive statistics for ECG parameters and changes from baseline will be presented by 
treatment group. Shift tables will present changes from baseline to end of treatment in ECG 
interpretation (categorized as normal; abnormal, not clinically significant; and abnormal, 
clinically significant). All ECG data will be displayed in listings. 
13.7.6 
Physical Examinations 
Descriptive statistics will be used to summarize physical examination results by treatment group 
and time point (Screening, Week 30 and Week 52). The number of subjects with findings of 
potential clinical significance will be tabulated. All physical examination data will be displayed 
in listings. 
13.7.7 
Focused Ears, Nose, and Throat and Eye Examinations 
Descriptive statistics will be used to summarize ENT and eye examination results by treatment 
group and time point (Week 30 and Week 52). The number of subjects with findings of potential 
clinical significance will be tabulated. All ENT and eye examination data will be displayed in 
listings. 
13.7.8 
Concomitant Medication and Withdrawals 
Any withdrawals from the study will be listed and summarized by reason for withdrawal, study 
treatment group and by any other relevant categorical information. Descriptive statistics will be 
used to summarize the number (%) of subjects who used rescue medication along with the type, 
dose, and duration of rescue medication. 
Concomitant medications, including rescue medications, will be listed. 
13.8 
Interim Analysis  
No interim analysis is planned for this study. 
14 QUALITY CONTROL AND QUALITY ASSURANCE 
The Sponsor or designee will implement and maintain quality assurance and quality control 
systems with Standard Operating Procedures (SOP) to ensure that this clinical study is conducted 
and data are generated, documented (recorded), and reported in compliance with the protocol, 
Good Clinical Practice (GCP) standards, ICH, and other applicable local regulations. 
Glenmark  
CONFIDENTIAL 
Page 60 of 91 

GSP 301-303 
GPL/CT/2014/018/III  
Version 2.0 
 
Date 31-Aug-2016 
The Sponsor is responsible for securing agreement among collaborating parties to ensure direct 
access to clinical-study-related sites and material to ensure that all data are reliable and have 
been processed correctly. 
14.1 
Procedures for Monitoring Compliance 
To ensure the completeness and accuracy of CRFs/eCRFs completion, each site will be 
monitored by a designated Clinical Study Monitor. At regular intervals, the study monitor will 
visit the study site(s). The frequency of visits will vary depending on the recruitment rate. It is 
the duty of the Investigator to provide open access to the monitor of all study related records at 
previously agreed upon times. The Sponsor, IRB/IEC, and regulatory authorities shall have right 
to direct access to source data for verification. 
14.2 
Inspection 
An inspection is defined as the act of a regulatory authority conducting an official review of 
documents, facilities, records, IRB, and any other resources that are deemed by the authorities to 
be related to the clinical study. These may be located at the site of the study, Sponsor and/or 
CRO facilities, or any other establishments deemed appropriate by the regulatory authorities. 
14.3 
Audit 
An audit is a systematic and independent review of study-related activities and documents to 
determine whether study-related activities were conducted and the data accurately recorded and 
analyzed according to the protocol, SOPs, GCP, and other appropriate requirements. 
In conducting this study, the Investigator accepts that the Sponsor, IRB/IEC, or regulatory body 
may, at any time by appointment, conduct an audit of the study site. 
15 ETHICS 
15.1 
Ethics Committee Approval 
The clinical study protocol, ICF, and any documents that are given to the study subjects (e.g., 
questionnaires, diaries, etc.) must be reviewed and approved by an IRB or IEC constituted and 
functioning in accordance with Section 3 of ICH E6 (GCP) and any local regulations. Any 
protocol amendment, or revision to the ICF or other documents used in the study, will be 
resubmitted to the IRB/IEC for review and approval. Documentation of IRB/IEC compliance 
with ICH E6 and any local regulations regarding constitution and review conduct will be 
provided to the Sponsor. 
Any queries raised by the IRB/IEC in regard to the study will be provided in writing to the 
Investigator. The Investigator will be responsible for providing answers and resolving all queries 
prior to study start. The Investigator must consult with the Sponsor before providing a response 
to the IRB/IEC. 
A signed letter of study approval from the IRB/IEC chairman must be sent to the Investigator or 
Sponsor, depending on local regulatory obligations, before study start and the release of any IP 
to the site by the Sponsor or its designee (ICH E6, Section 4.4). If the IRB/IEC decides to 
suspend or terminate the study, the Investigator (or if regionally required, the head of the medical 
Glenmark  
CONFIDENTIAL 
Page 61 of 91 

GSP 301-303 
GPL/CT/2014/018/III  
Version 2.0 
 
Date 31-Aug-2016 
institution) will immediately send the notice of study suspension or termination by the IRB/IEC 
to the Sponsor (or Investigator), as appropriate.  
Written approvals from the IRB/IEC and Regulatory Authority must be obtained before starting 
the informed consent process for the first subject at the site. The IRB/IEC will also review the 
ICF and endorse it in writing. 
Study progress will be reported to IRBs/IECs annually (or as required) by the Investigator or 
Sponsor, depending on local regulatory obligations. If the Investigator is required to report to the 
IRB/IEC, he/she will forward a copy to the Sponsor/designee at the time of each periodic report. 
The Investigator(s) or the Sponsor will submit, depending on local regulations, periodic reports 
and inform the IRBs/IECs (or if regionally required, the Investigator and the relevant IRB/IEC 
via the head of the medical institution) of any reportable AEs per ICH guidelines and local 
IRB/IEC standards of practice. Upon completion of the study, the Investigator will provide the 
IRBs/IECs with a brief report of the outcome of the study, if required. 
At the end of the study, the Investigator should notify the IRB/IEC and Regulatory Authority in 
accordance with local regulatory obligations. The end of the study will be the date of the last 
study visit for the last subject in the study. The Investigator or Sponsor, depending on local 
regulatory obligations, should also provide the IRB/IEC with an end-of-study notification. 
In the case of early termination/temporary halt of the study, the Investigator or Sponsor should 
notify the IRB/IEC and Regulatory Authority in accordance with applicable regulatory 
requirements, and a detailed written explanation of the reasons for the termination/halt should be 
given. 
15.2 
Ethical Conduct of the Study 
This study will be conducted in accordance with the SOPs of the Sponsor (or designee), which 
are designed to ensure adherence to GCP guidelines as required by the following: 
• Principles of the World Medical Association Declaration of Helsinki 2008. 
• ICH E6 Guideline for GCP.  
• Title 21 of the US Code of Federal Regulations (US 21 CFR) regarding clinical studies, 
including Part 50 and Part 56 concerning informed subject consent and IRB regulations 
and applicable sections of US 21 CFR Part 312. 
15.3 
Informed Consent/Assent Process 
The Investigator is responsible for obtaining informed consent from each subject/legally 
acceptable representative (LAR) participating in the study. All pertinent aspects of the study 
must be explained to the subject/LAR before he or she signs the ICF. Informed consent/assent 
must be obtained from the subject/LAR before any activity or treatment is undertaken which is 
not part of routine care. This includes, but is not limited to, the performance of diagnostic or 
therapeutic procedures and the administration of the first dose of the study medication. Each 
subject must be informed that participation in the study is voluntary, that he/she may withdraw 
from the study at any time, and that withdrawal of consent will not affect his/her subsequent 
medical treatment or relationship with the treating physician. 
Glenmark  
CONFIDENTIAL 
Page 62 of 91 

GSP 301-303 
GPL/CT/2014/018/III  
Version 2.0 
 
Date 31-Aug-2016 
This informed consent should be given by means of a standard written statement, written in 
nontechnical language. The subject/LAR should understand the statement before signing and 
dating it and will be given a copy of the signed document.  
Each subject/LAR must sign an approved ICF before study participation. The form must be 
signed and dated by the appropriate parties. The original, signed ICF for each subject will be 
verified by the Sponsor and kept on file according to local procedures at the site.  
The subject or the subject’s LAR should be informed in a timely manner if new information 
becomes available that may be relevant to the subject’s willingness to continue participation in 
the study. The communication of this information should be documented. If required, informed 
consent should be obtained using an amended ICF for the subject’s continuation in the study. 
15.4 
Approval of the Protocol and Amendments 
Subjects will not be admitted to the study before approval of the study protocol and other 
relevant study documents by the IRB/IEC and Regulatory Authority. 
Any change or addition to this protocol requires a written protocol amendment that must be 
approved by the Sponsor, Principal Investigator and IRB/IEC before implementation. 
Amendments significantly affecting the safety of subjects, the scope of the investigation or the 
scientific quality of the study will require additional approval by the IRB/IEC and the Regulatory 
Authority, as appropriate. 
These requirements for approval will in no way prevent any immediate action from being taken 
by the Principal Investigator in the interest of preserving the safety of the subjects included in the 
study. If an immediate change to the protocol is considered necessary by the Principal 
Investigator and is implemented for safety reasons, the IRB/IEC will be informed within 7 
working days. Changes affecting only administrative aspects of the study will not require formal 
protocol amendments or IRB/IEC approval, but the IRB/IEC will be kept informed of such 
administrative changes. 
Protocol changes that affect only administrative aspects of the study may not require submission 
to Health or Regulatory Authority or the IRB/IEC, but the Health or Regulatory Authority and 
IRB/IEC should be kept informed of such changes as required by local regulations. In these 
cases, the Investigator or Sponsor, may be required to send a letter to the IRB/IEC and the 
Regulatory Authorities notifying them of such changes. 
15.5 
Protocol Deviation 
Any deviation from the protocol will be recorded as a protocol deviation in the CRF/eCRF and 
reported to the IRB per IRB policy. 
16 DATA HANDLING AND RECORD KEEPING 
16.1 
Data Management 
Data from the study will be managed by the Sponsor’s Clinical Research Operations group or 
designee. A copy of the study results will be made available to the Clinical Investigator for 
review. 
Glenmark  
CONFIDENTIAL 
Page 63 of 91 

GSP 301-303 
GPL/CT/2014/018/III  
Version 2.0 
 
Date 31-Aug-2016 
All data will be directly recorded on the CRFs/eCRFs. The Investigator will allow 
representatives of the Sponsor, regulatory agencies, and their designees to inspect all study 
documents (including, but not limited to, consent forms, IP accountability forms, IRB/IEC 
approvals) and pertinent hospital or clinic records for confirmation of data throughout and after 
completion of the study. Monitoring visits will be conducted as needed during the course of the 
study. A complete review of source documentation of key efficacy and safety data will be 
conducted at each monitoring visit for verification that all information recorded in the 
CRF/eCRF accurately reflects the data recorded in the subject's source documents. 
All data verification, using hospital or clinic records, will be performed respecting subject 
confidentiality and will be carried out in accordance with local SOPs.  
All subject data generated during the study will be recorded and transcribed in the CRF/eCRF. 
The Principal Investigator must approve the CRF/eCRF to confirm eligibility. The final 
authorization of the CRF/eCRF data is the Investigator Signature Form. This form must be 
approved by the Principal Investigator to signify that he/she has reviewed the CRF/eCRF, 
including all laboratory and safety assessments, and that all of the data therein is complete and 
accurate.   
The data will be reviewed to ensure that the forms were completed appropriately and that all data 
has the correct subject identification number.  
16.2 
Direct Access to Source Data/Documents 
Essential demographic data will be documented both within the subject’s medical record notes 
(source data) and within the study CRF/eCRF and be available for inspection by the Sponsor’s 
Clinical Study Monitor, including electronic records. Source data will also include date of 
consent, time of drug administration and blood sampling, together with vital signs recorded at 
each visit. 
It is the responsibility of the Investigator(s) to maintain accurate and up to date records of all 
clinical study related activities, which should be entered on the source documents and 
CRFs/eCRFs provided. The CRFs/eCRFs should be made available to the Clinical Study 
Monitor on request, and in the event of a formal investigational site audit. 
16.3 
Confidentiality and Intellectual Property 
All information disclosed to the Investigator by the Sponsor or persons assigned by the Sponsor 
shall be treated by the Investigator as strictly confidential. The Investigator shall only use such 
information for the purpose of conducting the clinical study described in this protocol and agrees 
not to disclose such information to any third party except his/her colleagues and employees 
assisting in the conduct of the study and who are bound by the obligations of confidentiality. 
Information concerning the IP, patent applications, processes, unpublished scientific data, the IB, 
and other pertinent information is confidential and remains the property of the Sponsor. Details 
should be disclosed only to the persons involved in the approval or conduct of the study. The 
Investigator may use this information for the purpose of the study only. It is understood by the 
Investigator that the Sponsor will use the information obtained during the clinical study in 
connection with the development of the drug and therefore may disclose it as required to other 
clinical Investigators or to regulatory agencies. In order to allow for the use of the information 
derived from this clinical study, the Investigator understands that he/she has an obligation to 
Glenmark  
CONFIDENTIAL 
Page 64 of 91 

GSP 301-303 
GPL/CT/2014/018/III  
Version 2.0 
 
Date 31-Aug-2016 
provide the Sponsor with all data obtained during the study. The Institution and/or the 
Investigator undertake that they will not reverse-engineer, decompile or dissemble the 
information, or make any variant out of the information. 
All intellectual property arising out of, or in connection with, the conduct of the clinical study 
described in this protocol (“Derivative Intellectual Property”) shall be promptly disclosed to the 
Sponsor. Any such Derivative Intellectual Property shall be the sole property of the Sponsor. The 
Institution and/or the Investigator, its affiliates and any person claiming through them shall do all 
acts and things as shall be necessary to vest all right, title and interest therein in the Sponsor. The 
Institution and/or the Investigator shall keep the said Derivative Intellectual Property confidential 
in accordance with this Agreement. 
In the event of inconsistency between the above and the study contract, the terms of the study 
contract prevail to the extent of such inconsistency. 
16.4 
Record Retention 
On completion of the study, electronic copies of all CRFs/eCRFs (if generated) or the paper 
copies of the entire raw data generated during the study will be provided to the investigational 
site for safekeeping for the duration stipulated by ICH GCP (currently 15 years or last marketing 
authorization, whichever is later).  
17 FINANCING AND INSURANCE 
The Sponsor will provide insurance for any subjects participating in the study in accordance with 
all applicable laws and regulations. 
18 PUBLICATION POLICY 
The Sponsor recognizes and supports the publication and dissemination of scientific information 
as a means of furthering knowledge. The general strategy regarding publication of the study 
(e.g., what, when, where, etc.) will be mutually agreed upon by the Investigator and Sponsor. 
However, in order to protect its commercial interests, the Sponsor reserves the right to manage 
the publication of all study results. The Investigator agrees that oral and written communication 
to third parties of any procedures or results from the study is subject to prior written consent of 
the Sponsor. Presentation material(s) and/or manuscript(s) for publication will be reviewed by 
Sponsor prior to submission for publication. This review will be completed within 30 days of 
receiving presentation material(s) and 60 days of receiving the manuscript(s) from the 
Investigator. Alterations in the material will only be made in agreement between the Investigator 
and the Sponsor.  
In the event of inconsistency between the above and the study contract, the terms of the study 
contract prevail to the extent of such inconsistency. 
19 DISCONTINUATION OF STUDY 
The Sponsor reserves the right to discontinue the study for medical reasons or any other reason at 
any time. If a study is prematurely terminated or suspended, the Sponsor will promptly inform 
the Investigators/Institutions and Regulatory Authorities of the termination or suspension and the 
reason(s) for the termination or suspension. The IRB/IEC will also be informed promptly and 
Glenmark  
CONFIDENTIAL 
Page 65 of 91 

GSP 301-303 
GPL/CT/2014/018/III  
Version 2.0 
 
Date 31-Aug-2016 
provided the reason(s) for the termination or suspension by the Sponsor or by the 
Investigator/Institution, as specified by the applicable regulatory requirement(s). 
The Investigator reserves the right to discontinue the study should his/her judgment so dictate. If 
the Investigator terminates or suspends a study without prior agreement of the Sponsor, the 
Investigator should inform the Institution where applicable, and the Investigator/Institution 
should promptly inform the Sponsor and the IRB/IEC and provide the Sponsor and the IRB/IEC 
with a detailed written explanation of the termination or suspension. Study records must be 
retained as noted above. 
20 REFERENCES 
1. 
Tran NP, Vickery J, Blaiss MS. Management of rhinitis: allergic and non-allergic. 
Allergy Asthma Immunol Res. 2011;3:148-156. 
2. 
Naclerio RM, Bachert C, Baraniuk JN. Pathophysiology of nasal congestion. Internatl J 
of Gen Med. 2010;3:47-57. 
3. 
Rosenwasser LJ, O'Brien T, Weyne J. Mast cell stabilization and anti-histamine effects of 
olopatadine ophthalmic solution: a review of pre-clinical and clinical research. Curr Med 
Res Opin. 2005;21:1377-1387. 
4. 
Kaliner MA, Oppenheimer J, Farrar JR. Comprehensive review of olopatadine: the 
molecule and its clinical entities. Allergy & Asthma Proc. 2010;31:112-119. 
5. 
Min YG. The pathophysiology, diagnosis and treatment of allergic rhinitis. Allergy 
Asthma Immunol Res. 2010;2:65-76. 
6. 
Okano M. Mechanisms and clinical implications of glucocorticosteroids in the treatment 
of allergic rhinitis. Clin & Exp Immunol. 2009;158:164-173. 
7. 
Shapiro G, Nassef M. Rhinitis: a practical approach. Postgraduate Institute for Medicine, 
Respiratory and Allergic Disease (RAD) Foundation and MedPointe Pharmaceuticals. 
Oct 2005. 
8. 
Nasser M, Fedorowicz Z, Aljufairi H, McKerrow W. Antihistamines used in addition to 
topical nasal steroids for intermittent and persistent allergic rhinitis in children. Cochrane 
Database of Systematic Reviews. 2010;7:Article ID CD006989.  
9. 
US Prescribing Information: PATANASE (olopatadine hydrochloride) Nasal Spray; 
Initial US Approval: 2009; Revised: Aug 2012. 
10. 
US Prescribing Information: NASONEX (mometasone furoate monohydrate) Nasal 
Spray; Initial US Approval: 1997; Revised: Aug 2013. 
11. 
Center for Drug Evaluation and Research. Pharmacological Review of NASONEX® 
Nasal Spray. NDA No. 20-762. 
12. 
Center for Drug Evaluation and Research. Pharmacology/Toxicology Review and 
Evaluation of PATANASE® Nasal Spray. NDA No. 21-861. 
13. 
Center for Drug Evaluation and Research. Pharmacological Review of PATANASE® 
Nasal Spray. NDA No. 20-688. 
Glenmark  
CONFIDENTIAL 
Page 66 of 91 

GSP 301-303 
GPL/CT/2014/018/III  
Version 2.0 
 
Date 31-Aug-2016 
14. 
Center for Drug Evaluation and Research. Guidance for Industry. Allergic Rhinitis: 
Clinical Development Programs for Drug Products. Apr 2000. 
15. 
US Prescribing Information: DYMISTA (azelastine hydrochloride and fluticasone 
propionate) Nasal Spray. Initial US Approval: 2012; Revised: Feb 2015. 
16. 
van Bavel JH, Ratner PH, Amar NJ, Hampel FC Jr, Melchior A, Dunbar SA, et al. 
Efficacy and safety of once-daily treatment with beclomethasone dipropionate nasal 
aerosol in subjects with seasonal allergic rhinitis. Allergy Asthma Proc. 
2012;33:386-396. 
17. 
Juniper EF and Guyatt HG. Development and testing of a new measure of health status 
for clinical trials in rhinoconjunctivitis. Clin & Exp Allergy. 1999;21:77-83. 
18. 
Meltzer EO, Schatz M, Nathan R, Garris C, Stanford RH, Kosinski M. Reliability, 
validity, and responsiveness of the rhinitis control assessment test in patients with 
rhinitis. J Allergy Clin Immunol. 2013;131:379-386. 
19. 
ICH E1. The Extent of Population Exposure to Assess Clinical Safety for Drugs Intended 
for Long-Term Treatment of Non-Life-Threatening Conditions. Oct 1994. 
20. 
Spector S. Ideal pharmacotherapy for allergic rhinitis. J Allergy Clin Immunol. 
1999;103:S386-S387. 
21. 
Salapatek AM, Lee J, Patel D, D’Angelo P, Liu J, Zimmero RO Jr., et al. Solubilized 
nasal steroid (CDX-947) when combined in the same solution nasal spray with an 
antihistamine (CDX-313) provides improved, fast-acting symptom relief in patients with 
allergic rhinitis. Allergy Asthma Proc. 2011;32:221–229. 
Glenmark  
CONFIDENTIAL 
Page 67 of 91 

GSP 301-303 
GPL/CT/2014/018/III  
Version 2.0 
 
Date 31-Aug-2016 
21 APPENDICES 
 
 
Glenmark  
CONFIDENTIAL 
Page 68 of 91 

GSP 301-303 
 
GPL/CT/2014/018/III  
Version 2.0 
 
 
Date 31-Aug-2016 
 
21.1 
Appendix 1: Schedule of Procedures and Assessments 
Visits 
Screening 
Visit (SV) 
Visit 1 
Randomization 
Visit (RV) 
Visit 2 
Treatment Visits (TV) 
Final Visit / 
Discontinuation  
Visit (FV/DV) 
Visit 12 
TV 3 
TV4 
TV 5 
TV 6 
TV 7 
TV 8 
TV 9 
TV 10 
TV 11 
Week 
-1 
1 
3 
6 
12 
18 
24 
30 
36 
42 
48 
52 
Day ± Window 
(-7 to -10) 
1 
22±3 
43±3 
85±5 
127±7 
169±7 
211±7 
253±7 
295±7 
337±7 
365+10 
Activity / Observation 
Written informed consent (assent, 
if applicable) and HIPAA 
authorization 
X 
 
 
 
 
 
 
 
 
 
 
 
Inclusion/exclusion criteria 
review 
X 
 
 
 
 
 
 
 
 
 
 
 
Demographic data 
X 
 
 
 
 
 
 
 
 
 
 
 
Medical & treatment history  
X 
 
 
 
 
 
 
 
 
 
 
 
Concomitant medication 
evaluation 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
Physical examination  
X 
 
 
 
 
 
 
X 
 
 
 
X 
Vital signs 
X 
X 
 
 
 
 
 
X 
 
 
 
X 
Height and weight measurements 
X 
 
 
 
 
 
 
X 
 
 
 
X 
Clinical laboratory investigations 
(hematology, biochemistry, 
urinalysis)a 
X 
 
 
 
 
 
 
X 
 
 
 
X 
Glenmark  
CONFIDENTIAL 
Page 69 of 91 

GSP 301-303 
 
GPL/CT/2014/018/III  
Version 2.0 
 
 
Date 31-Aug-2016 
 
Visits 
Screening 
Visit (SV) 
Visit 1 
Randomization 
Visit (RV) 
Visit 2 
Treatment Visits (TV) 
Final Visit / 
Discontinuation  
Visit (FV/DV) 
Visit 12 
TV 3 
TV4 
TV 5 
TV 6 
TV 7 
TV 8 
TV 9 
TV 10 
TV 11 
Week 
-1 
1 
3 
6 
12 
18 
24 
30 
36 
42 
48 
52 
Day ± Window 
(-7 to -10) 
1 
22±3 
43±3 
85±5 
127±7 
169±7 
211±7 
253±7 
295±7 
337±7 
365+10 
Focused ENT and eye 
examinationb 
X 
X 
X 
X 
X 
 
 
X 
X 
X 
X 
X 
X 
X 
Allergen testing (skin prick test 
for relevant allergen, if required)c 
X 
 
 
 
 
 
 
 
 
 
 
 
 
12-lead ECG 
X 
 
 
 
 
 
 
 
 
 
 
X 
Urine pregnancy test (if 
applicable) 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
Review instructions and train on 
the proper use of the nasal spray 
using the GSP 301 placebo NS 
7 bottle 
X 
 
 
 
 
 
 
 
 
 
 
 
Review instructions and train on 
the proper use of the nasal spray 
 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
 
Prime and dispensation and 
administration of single-blind 
GSP 301 placebo NS 
7 at 
the clinicd 
X 
 
 
 
 
 
 
 
 
 
 
 
Return single-blind GSP 301 
placebo NS 
 to the clinice 
 
X 
 
 
 
 
 
 
 
 
 
 
Distribution of the AR 
Assessment Diary 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
 
Glenmark  
CONFIDENTIAL 
Page 70 of 91 

GSP 301-303 
 
GPL/CT/2014/018/III  
Version 2.0 
 
 
Date 31-Aug-2016 
 
Visits 
Screening 
Visit (SV) 
Visit 1 
Randomization 
Visit (RV) 
Visit 2 
Treatment Visits (TV) 
Final Visit / 
Discontinuation  
Visit (FV/DV) 
Visit 12 
TV 3 
TV4 
TV 5 
TV 6 
TV 7 
TV 8 
TV 9 
TV 10 
TV 11 
Week 
-1 
1 
3 
6 
12 
18 
24 
30 
36 
42 
48 
52 
Day ± Window 
(-7 to -10) 
1 
22±3 
43±3 
85±5 
127±7 
169±7 
211±7 
253±7 
295±7 
337±7 
365+10 
Collection/Review of the AR 
Assessment Diary 
 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
Subject assessment of AR 
symptoms and recording and self-
administration of placebo run-in 
medicationd 
Xd 
 
 
 
 
 
 
 
 
 
 
 
Subject assessment of AR 
symptoms and recording and self-
administration of double-blind 
study medicationd 
 
X 
 
 
 
 
 
 
 
 
 
 
Physician assessment of nasal 
symptom severity 
 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
Review randomization criteria 
 
X 
 
 
 
 
 
 
 
 
 
 
Randomization/treatment 
assignment 
 
X 
 
 
 
 
 
 
 
 
 
 
Prime and dispensation of 
double-blind study medication 
 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
 
Administration of double-blind 
study medication at the clinicd 
 
X 
 
 
 
 
 
 
 
 
 
 
Return double-blind study 
medication to the clinice 
 
 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
Distribution of the RQLQ(S), 
review instructions with the 
subject, and subject completion 
of the RQLQ(S)f 
 
X 
 
X 
 
 
 
X 
 
 
 
X 
RCAT 
 
X 
 
X 
 
 
 
X 
 
 
 
X 
Glenmark  
CONFIDENTIAL 
Page 71 of 91 

GSP 301-303 
 
GPL/CT/2014/018/III  
Version 2.0 
 
 
Date 31-Aug-2016 
 
Visits 
Screening 
Visit (SV) 
Visit 1 
Randomization 
Visit (RV) 
Visit 2 
Treatment Visits (TV) 
Final Visit / 
Discontinuation  
Visit (FV/DV) 
Visit 12 
TV 3 
TV4 
TV 5 
TV 6 
TV 7 
TV 8 
TV 9 
TV 10 
TV 11 
Week 
-1 
1 
3 
6 
12 
18 
24 
30 
36 
42 
48 
52 
Day ± Window 
(-7 to -10) 
1 
22±3 
43±3 
85±5 
127±7 
169±7 
211±7 
253±7 
295±7 
337±7 
365+10 
Adverse events monitoring 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
Subject compliance check  
 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
Abbreviations: AM = morning; AR = allergic rhinitis; ECG = electrocardiogram; ENT = ears, nose, and throat; HIPAA = Health Insurance Portability and 
Accountability Act; NS = nasal spray; RQLQ(S) = Rhinoconjunctivitis Quality of Life Questionnaire - Standardized Activities; RCAT = Rhinitis Control 
Assessment Test. 
a  Refer to Appendix 3 
List of Clinical Laboratory Tests 
b  A focused ENT and eye examination will be done at all visits. Focused nasal examinations will be performed to assess signs of AR as well as known 
complications of intranasal corticosteroid or antihistamine use (i.e., bleeding, perforation, and ulceration). Throat examinations will be conducted to evaluate 
evidence of throat irritation and candidiasis. . If at any visit, clinically significant nasal ulceration, nasal mucosal erosion, and nasal septal perforation are 
observed, or a finding at a previous visit has worsened (as judged by the Investigator), the subject should be referred to a qualified ENT specialist or other 
medically qualified specialist (qualified to evaluate and record these conditions, as judged by the Investigator) for further evaluation. A record from the specialist 
should be maintained, including the photographic evidence (imaging of nasal mucosa) of the assessment to allow pre- and post-treatment comparisons for AEs 
(see details in Section 12.4.11). The Sponsor will collect the de-identified information as part of the study data collection. Eligibility of the subject for 
participation/continued participation in the study will be at the Investigator’s discretion based on whether or not the protocol-defined selection criteria are met. 
These subjects may need to be re-screened due to delay in scheduling an ENT visit to obtain the necessary evaluation, as applicable, upon consultation with the 
Sponsor’s study team and approval. A thorough eye examination will also be performed by the Investigator or medically qualified designee to assess signs of AR 
as well as any known complications of intranasal corticosteroid or antihistamine use. If needed, the subject should be referred to a qualified ophthalmologist for 
further evaluation as soon as possible. 
c  Documentation of a positive result within the last year (12 months) before the Screening Visit (Visit 1) is acceptable to meet the eligibility criteria. Intradermal 
and/or RAST testing will not be accepted. 
d  Generally, subjects will assess/record AR symptoms and take study medication at home. Subjects will assess their symptoms at specified clinic visits, as 
directed by the site personnel. The subject assessment and recording of AR symptoms will be done at the clinic at the Screening Visit (Visit 1) and study 
medication will be self-administered in the clinic at the Screening Visit (Visit 1) and the Randomization Visit (Visit 2). Morning doses of study medication 
during the run-in and treatment periods should be taken immediately following completion of the AR Assessment Diary (as applicable) except on the morning of 
the Screening Visit (Visit 1) and Randomization Visit (Visit 2) when the first dose of the placebo run-in medication and the double-blind study
respectively, will be self-administered in the clinic under the supervision of site personnel.
doses of study medication should be
 At the Screening Visit (Visit 1), subjects should be told not to ta e study medication before coming to the cli
Glenmark  
CONFIDENTIAL 
Page 72 of 91 

GSP 301-303 
 
GPL/CT/2014/018/III  
Version 2.0 
 
 
Date 31-Aug-2016 
 
Randomization Visit (Visit 2). The last dose of the double-blind study medication should be the
dose on the day before the Final Visit/Discontinuation Visit 
(Visit 12). Subjects should be reminded not to take study medication on the morning of the Final Visit/Discontinuation Visit (Visit 12). 
e  Subjects should be instructed to bring their study medication kit to each visit after the Screening Visit (Visit 1). Site personnel will collect the kit, take the used 
study medication, and return the rest of the kit to the subject, as applicable. 
f  The RQLQ(S) must be the first procedure conducted at these visits. 
 
Glenmark  
CONFIDENTIAL 
Page 73 of 91 

GSP 301-303 
GPL/CT/2014/018/III  
Version 2.0 
 
Date 31-Aug-2016 
 
21.2 
Appendix 2: Subject Instructions for Proper Use of Nasal Spray Bottle  
Subjects will administer their assigned study medication on their own (self-administration) 
using the subject instructions below. If needed, parents/guardians/caregivers can 
assist subjects with administering the study nasal spray medication (helping the subject perform 
certain tasks to ensure that the bottle is used properly); however, they should be reminded that 
“you” as stated in the instructions below, refers to the subject and not the person assisting the 
subject.  
Preparing the Nasal Spray Bottle for Use (prior to the first use ONLY)  
As with all nasal spray medications, the bottle must be primed prior to the first use. The priming 
process must be performed by the study personnel but away from the study subjects to avoid any 
possible inhalation and contamination. 
Priming should be done as follows: 
• Nasal spray bottle should be shaken well before priming. 
• Remove the protective (dust) cap from the bottle. 
• Hold the nasal spray bottle firmly with your index and middle finger on either side of the 
applicator (on finger rests) while supporting the base of the bottle with your thumb. 
• Release 6 sprays into the air, away from the eyes and face, by pressing down and 
releasing the pump 6 times. 
Using Nasal Spray Bottle
 
Shake the bottle well before each use (morning and evening). 
1. Blow your nose to clear your nostrils. 
2. Remove the dust cap from the nasal spray bottle. 
3. Hold the bottle firmly with your index and middle finger on either side of the applicator 
(on finger rests) while supporting the base of the bottle with your thumb. 
4. Insert the end of the nasal tip into 1 nostril, pointing it slightly toward the outside nostril 
wall away from the nasal septum (the wall between the 2 nostrils), while holding your 
other nostril closed with 1 finger. 
5. Tilt your head forward slightly. Keep the bottle upright, and press down the finger rests 
quickly and firmly to activate the pump. Breathe in (inhale) gently through your nose as 
you spray. Then breathe out through your mouth. Try not to get any spray in your eyes or 
directly on your nasal septum (the wall between the 2 nostrils). 
6. 
Glenmark  
CONFIDENTIAL 
Page 74 of 91 

GSP 301-303 
GPL/CT/2014/018/III  
Version 2.0 
 
Date 31-Aug-2016 
 
7. 
8. Replace the protective (dust) cap on the nasal spray bottle. 
9. Avoid blowing your nose for the next 15 minutes. Do not tip your head back or blow 
your nose right after using the nasal spray. This will help to keep the medicine from 
going into your throat. 
Notes: 
• You will be given study medication kits. Remember to take your study medication 
treatment
• Prime the nasal spray bottle only 1 time (releasing 6 sprays) prior to the First Use if this 
was not done at the clinic. DO NOT prime the bottle every day. In some instances, study 
personnel may ask you to prime a new bottle at home prior to the first use. 
• If unused for more than 1 week, reprime by spraying 2 times following the priming 
instructions.  
• This medicine is for use in the nose only. Avoid spraying in your eyes. 
• Shake well before each use (morning and evening). 
• After you finish administering the medication, wipe the tip with a clean dry tissue or 
cloth, replace the cap, and store the nasal spray bottle in an upright position in the bottle 
carton. 
• Store study medication between 15°C and 25°C (59°F and 77°F). 
• If the nasal spray bottle appears to be blocked or not spraying properly, contact your 
study site/doctor immediately. 
• Please contact your study nurse/coordinator or study doctor immediately if you have 
questions regarding the use of your medications. 
 
 
 
Glenmark  
CONFIDENTIAL 
Page 75 of 91 

GSP 301-303 
GPL/CT/2014/018/III  
Version 2.0 
 
Date 31-Aug-2016 
 
21.3 
Appendix 3 
List of Clinical Laboratory Tests 
Safety Laboratory Test Panels 
Serum Chemistry 
Hematology 
Urinalysis  
Glucose  
Blood urea nitrogen   
Creatinine 
Sodium 
Potassium  
Calcium  
Chloride  
Bicarbonate  
Bilirubin, direct bilirubin  
Alkaline phosphatase  
Aspartate aminotransferase 
(=SGOT)  
Alanine aminotransferase 
(=SGPT)  
Gamma glutamyl transferase  
Total protein  
Albumin  
 
Hemoglobin  
Erythrocytes  
Mean corpuscular volume 
Platelets  
Reticulocytes (absolute) 
Leukocytes  
Differential (absolute and 
percent): 
Eosinophils  
Basophils  
Neutrophils  
Lymphocytes  
Monocytes  
Coagulation 
Activated partial thromboplastin 
time  
Prothrombin time 
Prothrombin time International 
Normalized Ratio  
Urine protein  
pH 
Urine blood  
Specific gravity  
Urine ketones  
Urine bilirubin  
Urine glucose  
Leukocytes  
 
 
Glenmark  
CONFIDENTIAL 
Page 76 of 91 
 

GSP 301-303 
GPL/CT/2014/018/III  
Version 2.0 
 
Date 31-Aug-2016 
 
21.4 
Appendix 4: Rhinoconjunctivitis Quality-Of-Life Questionnaire with Standardized 
Activities 
General Instructions: 
1. This must be the first procedure performed at the visit. 
2. A paper version of RQLQ(S) will be provided to subjects. 
3. Subjects should be placed in a quiet room to fill out the RQLQ(S). 
4. Subjects must complete the questionnaire on their own. 
5. All friends/relatives/caregivers should be asked to wait in a separate room. 
6. Clinical coordinators/study site personnel should never assist the subjects in answering any 
question on the RQLQ(S). The best approach is to repeat the question exactly as it is worded in 
the questionnaire, if consulted. Under no circumstances should the question be reworded in 
an attempt to explain it to the subjects. 
 
Specific Instructions for the Clinical Coordinators/Site Personnel Prior to Subjects 
Completing the RQLQ(S): 
 
The clinical staff must: 
1. Tell subjects that all questions on the questionnaire (28 questions) must be answered. 
 
2. Tell subjects that only 1 response may be given for each question. 
 
3. Remind subjects that they are scoring limitations experienced specifically related to allergic 
rhinitis and not because of any other problems they may be experiencing. 
 
4. Remind subjects that they should focus on the limitations due to allergic rhinitis that have 
occurred within the last week. 
 
5. Tell subjects that they need to circle the number for each question that most closely matches 
how their allergy symptoms have affected their life within the past week. 
 
After the subject has completed the RQLQ(S), the clinical coordinator/site personnel should 
review the completed questionnaire to ensure that all questions have been answered. 
 
 
 
Glenmark  
CONFIDENTIAL 
Page 77 of 91 
 

GSP 301-303 
GPL/CT/2014/018/III  
Version 2.0 
 
Date 31-Aug-2016 
 
 
Glenmark  
CONFIDENTIAL 
Page 78 of 91 
 

GSP 301-303 
GPL/CT/2014/018/III  
Version 2.0 
 
Date 31-Aug-2016 
 
 
Glenmark  
CONFIDENTIAL 
Page 79 of 91 
 

GSP 301-303 
GPL/CT/2014/018/III  
Version 2.0 
 
Date 31-Aug-2016 
 
 
Glenmark  
CONFIDENTIAL 
Page 80 of 91 
 

GSP 301-303 
GPL/CT/2014/018/III  
Version 2.0 
 
Date 31-Aug-2016 
 
 
Glenmark  
CONFIDENTIAL 
Page 81 of 91 
 

GSP 301-303 
GPL/CT/2014/018/III  
Version 2.0 
 
Date 31-Aug-2016 
 
 
 
 
Glenmark  
CONFIDENTIAL 
Page 82 of 91 
 

GSP 301-303 
GPL/CT/2014/018/III  
Version 2.0 
 
Date 31-Aug-2016 
 
21.5 
Appendix 5: Rhinitis Control Assessment Test 
This questionnaire asks about your nasal and other allergy symptoms that are not related to a 
cold or the flu, and the control of these symptoms. For each question, please choose the response 
that best describes your nasal and other allergy symptoms.   
1. During the past week, how often did you have nasal congestion?  
 
Never 
Rarely 
Sometimes 
Often 
Extremely often 
5 
4 
3 
2 
1 
 
2. During the past week, how often did you sneeze?  
 
Never 
Rarely 
Sometimes 
Often 
Extremely often 
5 
4 
3 
2 
1 
 
3. During the past week, how often did you have watery eyes?  
 
Never 
Rarely 
Sometimes 
Often 
Extremely often 
5 
4 
3 
2 
1 
 
4. During the past week, to what extent did your nasal or other allergy symptoms interfere with 
your sleep? 
 
Not at all 
A little 
Somewhat 
A lot 
All the time 
5 
4 
3 
2 
1 
 
5. During the past week, how well were your nasal or other allergy symptoms controlled? 
 
Glenmark  
CONFIDENTIAL 
Page 83 of 91 
 

GSP 301-303 
GPL/CT/2014/018/III  
Version 2.0 
 
Date 31-Aug-2016 
 
Completely 
Very 
Somewhat 
A little 
Not at all 
5 
4 
3 
2 
1 
 
6. During the past week, how often did you avoid any activities (for example, visiting a house 
with a dog or cat, gardening) because of your nasal or other allergy symptoms? 
 
Never 
Rarely 
Sometimes 
Often 
Extremely often 
5 
4 
3 
2 
1 
 
 
 
 
Glenmark  
CONFIDENTIAL 
Page 84 of 91 
 

GSP 301-303 
GPL/CT/2014/018/III  
Version 2.0 
 
Date 31-Aug-2016 
 
Scoring 
Responses to the questions will be scored as indicated by the number next to the response box as 
shown in tables below. The total RCAT score should be calculated by adding individual numbers 
(the simple algebraic sum of the final item scores for each RCAT item) answered for each 
question. The total RCAT score can range from 6 to 30. 
Scoring for Questions 1, 2, 3 and 6 
Response Choices 
Final Item Value 
Never 
5 
Rarely 
4 
Sometimes 
3 
Often 
2 
Extremely often 
1 
 
Scoring for Question 4 
Response Choices 
Final Item Value 
Not at all 
5 
A little 
4 
Somewhat 
3 
A lot 
2 
All of the time 
1 
 
 
 
Glenmark  
CONFIDENTIAL 
Page 85 of 91 
 

GSP 301-303 
GPL/CT/2014/018/III  
Version 2.0 
 
Date 31-Aug-2016 
 
 
Scoring for Question 5 
Response Choices 
Final Item Value 
Completely 
5 
Very 
4 
Somewhat 
3 
A little 
2 
Not at all 
1 
 
 
 
Glenmark  
CONFIDENTIAL 
Page 86 of 91 
 

GSP 301-303 
GPL/CT/2014/018/III  
Version 2.0 
 
Date 31-Aug-2016 
 
21.6 
Appendix 6: List of Contact Details  
 
Additional information and contact details related to the study will be provided to each clinical 
site separately in relevant documents and procedural manuals. 
 
SAE and Pregnancy Reporting: 
Fax:  + 44 1923 251137 
Email:  GlobalClinicalSAE@glenmarkpharma.com 
 
Medical Monitor (CRO): 
Dr. Pa
anzio 
Novum PRS 
225 W. Station Square Drive 
Suite 200 
Pittsburgh, PA 15219 
Tel: 1-412-363-3300 x 597 
PMFanz
prs.com 
 
Medical Monitor (Glenmark): 
Cynthia F
D, FCCP 
Vice President, Clinical Sciences-Respiratory 
Glenmark Pharmaceuticals Inc.  
750 Corporate Drive, Mahwah, NJ 07430, USA 
Office:  1-201-684-8015 
Mobile: 1-201-675-9443 
cynthia.car
pharma.com 
 
 
 
 
 
 
 
 
 
 
 
Glenmark  
CONFIDENTIAL 
Page 87 of 91 
 

GSP 301-303 
GPL/CT/2014/018/III  
Version 2.0 
 
Date 31-Aug-2016 
 
21.7 
Appendix 7: GSP 301-303 Protocol Amendment 1.0  
 
 
PROTOCOL NUMBER: GPL/CT/2014/018/III 
Study Number: GSP 301-303 
PROTOCOL AMENDMENT 1.0 
SUMMARY OF CHANGES 
  
 
A Double-Blind, Randomized, Parallel-Group Study to Evaluate  
Long-Term Safety, Tolerability, and Efficacy of a Fixed Dose Combination  
GSP 301 Nasal Spray Compared with Two Placebo Nasal Spray Formulations  
in Subjects (Aged 12 Years and Older) with Perennial Allergic Rhinitis (PAR) 
 
 
 
PROTOCOL HISTORY 
PROTOCOL VERSION 1.0 25-Jan-2016 
PROTOCOL VERSION 2.0 31-Aug-2016 
 
Glenmark  
CONFIDENTIAL 
Page 88 of 91 
 

GSP 301-303 
GPL/CT/2014/018/III  
Version 2.0 
 
Date 31-Aug-2016 
 
Description of Changes in Protocol Version 2.0 (Amendment 1.0) dated 31-Aug-2016 
Minor editorial changes for accuracy, clarity, and consistency have been made throughout the 
document and are not included in the description(s) below. 
 
Key:  
Bold: newly added text. 
Strikethrough: deleted text from the previous version of the protocol. 
A. Details of Substantial Changes to the Protocol.  
Not applicable 
 
B. Details of Non-substantial Changes to the Protocol: 
From 
Protocol Version 1.0  
25 Jan2015  
To  
Protocol Version 2.0  
(Amendment 1.0) 31-Aug-2016 
Rationale for Amendment 
1. Protocol synopsis, Section 9.3 Randomization Criteria and Section 13.5 Efficacy Analyses 
3. Minimum AM subject-reported 
rTNSS of an average of 5 (out of 
a possible 12) during the last 
4 days of the run-in period (last 4 
consecutive AM assessments 
from the Day -4 AM assessment 
to the AM assessment on the day 
of randomization). 
4. Has an AM subject-reported 
reflective nasal congestion score 
≥2 during the last 4 days of the 
run-in period (last 4 consecutive 
AM assessments from the Day -4 
AM assessment to the AM 
assessment on the day of 
randomization).  
5. Adequate AR Assessment Diary 
compliance – inadequate 
compliance is defined as missing 
1 or more of the entries on 2 or 
more assessment sessions (AM) 
during the last 4 days of the run-
in period (during the last 
4 consecutive AM assessments 
from the Day -4 AM assessment 
to the AM assessment on the day 
of randomization). 
Efficacy Analyses 
3. Minimum AM subject-reported 
rTNSS of an average of 5 (out of a 
possible 12) during the last 4 days 
of the run-in period (last 4 
consecutive AM assessments from 
the Day -3 Day -4 AM assessment 
to the AM assessment on the day 
of randomization). 
4. Has an AM subject-reported 
reflective nasal congestion score 
≥2 during the last 4 days of the 
run-in period (last 4 consecutive 
AM assessments from the Day -3 
Day – 4 AM assessment to the AM 
assessment on the day of 
randomization).  
5. Adequate AR Assessment Diary 
compliance – inadequate 
compliance is defined as missing 1 
or more of the entries on 2 or more 
assessment sessions (AM) during 
the last 4 days of the run-in period 
(during the last 4 consecutive AM 
assessments from the Day -3 Day -
4 AM assessment to the AM 
assessment on the day of 
randomization). 
Efficacy Analyses 
Typographical error corrected for 
clarification and accuracy: 
Changed Day -4 to Day -3. 
Glenmark  
CONFIDENTIAL 
Page 89 of 91 
 

GSP 301-303 
GPL/CT/2014/018/III  
Version 2.0 
 
Date 31-Aug-2016 
 
From 
Protocol Version 1.0  
25 Jan2015  
To  
Protocol Version 2.0  
(Amendment 1.0) 31-Aug-2016 
Rationale for Amendment 
Change from baseline in average AM 
subject-reported rTNSS and iTNSS 
over the first 6, 30, and 52 weeks of 
treatment will be analyzed using an 
analysis of covariance (ANCOVA) 
model adjusting for study treatment 
group, site, and baseline (defined as 
the average of the last 4 consecutive 
AM assessments during the last 4 
days of the run-in period from the 
Day -4 AM assessment to the AM 
assessment on the day of 
randomization). 
 
Change from baseline in average AM 
subject-reported rTNSS and iTNSS 
over the first 6, 30, and 52 weeks of 
treatment will be analyzed using an 
analysis of covariance (ANCOVA) 
model adjusting for study treatment 
group, site, and baseline (defined as the 
average of the last 4 consecutive AM 
assessments during the last 4 days of 
the run-in period from the Day -3 Day -
4 AM assessment to the AM 
assessment on the day of 
randomization). 
2. Appendix 2, Subject Instructions for Proper Use of Nasal Spray Bottle 
• 
Release 10 sprays into the 
air, away from the eyes and 
face, by pressing down and 
releasing the pump 10 
times. 
• 
Prime the nasal spray bottle 
only one time (releasing 10 
sprays) prior. 
 
• 
Release 6 10 sprays into the 
air, away from the eyes and 
face, by pressing down and 
releasing the pump 6 10 times. 
• 
Prime the nasal spray bottle 
only one time (releasing 6 10 
sprays) prior. 
The number of sprays (pressing 
down and release) required to 
prime the nasal spray has been 
reduced from 10 to 6. 
Based on additional analytical 
data it has been determined that 6 
sprays are adequate to prime the 
pumps for this nasal spray bottle.   
 
3. Appendix 6, List of Contact Details 
(New appendix, not in protocol 
version 1.0). 
The following information has been 
added: 
SAE and Pregnancy Reporting: 
Fax:  
+ 44 1923 251137 
Email:  
GlobalClinicalSAE@glenmarkphar
ma.com 
 
Medical Monitor (CRO) 
Dr. P
anzio 
Novum PRS 
225 W. Station Square Drive 
Suite 200 
Pittsburgh, PA 15219 
Tel: 1-(412) 363-3300 x 597 
The following information has 
been added for clarity: 
SAE and Pregnancy Reporting 
contact details 
CRO Medical Monitor contact 
details.  
Sponsor Medical Monitor contact 
details.  
 
 
Glenmark  
CONFIDENTIAL 
Page 90 of 91 
 

GSP 301-303 
GPL/CT/2014/018/III  
Version 2.0 
 
Date 31-Aug-2016 
 
From 
Protocol Version 1.0  
25 Jan2015  
To  
Protocol Version 2.0  
(Amendment 1.0) 31-Aug-2016 
Rationale for Amendment 
PMFanz
prs.com 
Medical Monitor (Glenmark): 
Cynthia F.
D, FCCP 
Vice President, Clinical Sciences-
Respiratory 
Glenmark Pharmaceuticals Inc.  
750 Corporate Drive, Mahwah, NJ 
07430, USA 
Office:  1-201-684-8015 
Mobile: 1-201-675-9443 
 
Glenmark  
CONFIDENTIAL 
Page 91 of 91